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1. ABSTRACT 
The success of allotransplantation has encouraged many physicians to refer ever-
increasing numbers of patients to transplant units to be considered for organ 
transplantation. Since there is a major scarcity of donor organs world-wide, the 
experimental search for human organs has focused on two alternatives; mechanical 
devices and cross-species transplants. The use of mechanical devices as substitute 
organs is understandably limited due to complications from trying to duplicate the 
function of complex organs such as the liver. This has resulted in a renewed interest 
in xenotransplantation. 
Organs from non-human primates would arguably be the organs of choice but ethical 
consideration prevents this. The transplantation ~f organs from pigs or sheep to 
humans i.e. xenotransplants, results in hyperacute rejection. The development of 
immunosuppressive agents such as Cyc1osporine A and Tacrolimus have significantly 
improved the survival of organ transplants. However, although there is a good 1-5 
year survival, the recurrent problem of chronic rejection still remains, and 
unresponsiveness to allografts has never been induced by these immunosuppressive 
agents. More importantly, the presence of adverse side effects including 
immunological complications and drug toxicity e.g. nephrotoxicity, remains a serious 
problem. 
Since the drugs currently available for allotransplantation preferably target T -cells, 
and are therefore unlikely to be sufficient for xenotransplantation where there is a 
strong B-cell driven response, there is a need for· new immunosuppressive agents. 
FTY720 (2 amino-2-(2-[ 4-octylphenyl] ethyl)-1,3-propanediol hydrochloride), a 
novel, immunosuppressive drug active in rodent and dog transplantation models, has 
shown no toxic side effects in pre-clinical studies although no long-term patient 
studies exist. The aim of this study was to evaluate the effect of FTY720 on the 
various components of the immune system in baboons as they are the species of 
choice for the pig-to-primate cardiac orthotopic xenotransplant. Three doses of 
FTY720 were studied in order to establish a dose response. The administration of 
0.3mg/kg FTY720 resulted in a marked decrease in circulating lymphocytes within 
four hours of treatment, reaching a 60-80% decrease within 24 hours. The effect of 
FTY720 was seen on both T and B-cells, the effect being more pronounced on T -cells 
but more sustained by B-cells. The reduction in CD4+ T -cells was slightly more rapid 
and more sustained than CD8+ T -cells. FTY720 was then tested at lower doses of 
O.lmg/kg and 0.03mg/kg. Although the response was more rapid and prolonged using 
a higher dosage, the maximum peripherallymphodepletion was comparable. 
Ex-vivo mitogen-induced whole blood cell proliferation was drastically decreased 
within hours after FTY720 treatment which suggests that the drug has a significant 
effect on the fimction of lymphocytes even at a low dose. The blood drug levels 
measured after the administration of FTY720 correlated favourably with the dose 
applied but not with the extent of lymphodepletion, suggestive of a high tissue 
distribution. FTY720 was well tolerated and no side effects were encountered. The 
drug was effective in terms of peripheral T and B-celllymphodepletion in baboons 
indicating it could be used in xenotransplantation. 
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The mode of action of FTY720 has not been elucidated although its molecular 
mechanism of immunosuppression has been reported to be either due to apoptosis of 
activated lymphocytes, or by homing to peripheral lymphoid tissue (lymph nodes, 
Peyer's Patches) through lymphocyte homing receptors including L-selectin. LTa. 
mice deficient in lymph nodes and Peyer's Patches, L-selectin knockout mice and 
control C57B1I6+ 1 29SV mice were administered Img/kg FTY720 in order to try to 
determine the mode of action of the drug. All the mice that received FTY720 showed 
a drastic reduction in both their white blood cell counts and in lymphocyte counts 
while those that received the vehicle i.e. distilled water, showed a very slight 
response. These results suggest that, in mice, the lymphocytes are eliminated rather 
than recruited to peripheral tissues, ·however, no ~poptotic assays were performed to 
confirm these findings. 
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2. INTRODUCTION 
2.1 Introduction to xenotransplantation 
The major scarcity of donor organs world-wide has resulted in a renewed interest in 
transplantation of organs across species. Xenotransplantation was pioneered by 
Reemtsma et al. (1964) who transplanted chimpanzee kidneys into human beings. 
Although the kidneys remained functional for nine months, attempts at transplanting 
other non-human primate organs were met with hyperacute rejection sometimes 
within hours of surgery. In addition, the use of non-human primates as organ donors 
for man is controversial and ethical consideration limits this. 
The transplantation of organs from disparate species e.g. pigs or sheep into humans 
would solve the critical shortage of allogeneic organs. The ease with which they can 
be bred in large numbers, their relative lack of pathogens, and the similarity of organ 
size attributes to pigs being a good alternative source for human organs. However, 
transplantation of organs from disparate species results in hyperacute rejection 
(HAR). Humans, apes and Old World monkeys have pre-existing natural antibodies 
that recognise oligo saccharides with a terminal Galal-3Gal structure (aGaI epitopes) 
which are present on porcine endothelial cells. This leads to complement (C1)-
mediated lysis of the graft endothelium and consequent rejection of the graft. The 
problem ofHAR has, to some extent, been successfully addressed by the 
neutralisation of these antibodies (Reding et al., 1989), C1 inhibition or deletion 
(Leventhal et aI., 1993), and donor organ hemoperfusion (Cooper et al., 1988). 
Although rejection of the xenografts was delayed considerably, graft rejection did 
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however occur within 3-4 days by a process known as delayed xenograft rejection 
(DXR). 
It is yet to be determined whether DXR can be overcome with conventional 
immlUlosuppression. Xu et al. (1997) achieved Ii nineteen-day survival in a 
discordant cardiac pig-to-baboon xenograft with pre-transplant total lymphoid 
irradiation combined with cyclosporine A (CsA) and methotrexate. Minanov et al. 
(1997) reported a slight prolongation of a cardiac pig-to-newbom baboon xenograft 
using cyclosporine-based triple immlUlosuppression~ but documented that the protocol 
was not able to prevent a humoral response which led to graft rejection. Waterworth 
et al. (1998) reported a three-week survival of a heterotopic heart xenotransplant (pig-
to-baboon) using an immlUlosuppressive regimen ofCsA, cyclophosphamide and 
steroids. 
It is becoming more evident that the prevention of graft rejection in 
xenotranspIantation involves not only the inhibition ofT-cells, but also other cell 
types, as the cells that infiltrate the xenografts consist mainly ofB cells~ natural killer 
cells (NK) and macrophages. Thus~ DXR rejection is mediated by both humoral and 
cellular mechanisms. An optimum immlUlosuppressive regimen that could inhibit the 
production of induced anti-xenograft antibodies should result in long-term survival 
and is therefore, essential to successful xenotransplantation. 
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2.2 Immunosuppression in allotransplantation 
Immunosuppressive drugs are classified into categories based on their principal 
mechanisms. CsA and Tacrolimus (FK506) inhibit the production ofinterleukin-2 
(IL-2) and interferon-y (INF-y) expression by activated T-cells (Kaufmann et al., 
1984; Kino et al., 1987; Bishop and Hall, 1988). Both CsA and FK506 have shown 
profound immunosuppressive effect on the prevention of acute rejection in clinical 
and experimental organ transplantation. Although these immunosuppressive drugs act 
on the same transduction pathway in the T -lymphocyte, namely by inhibiting 
calcineurin, some of their effects could be different, e.g. FK506 appears to decrease 
CD8 and local NK cell infiltration which could be mediated by FK506-induced IL-l 0 
suppression (Jiang et al., 1999). 
Rapamycin (Rapa) is structurally similar to FK506 and binds to the same intracellular 
binding protein but acts later than FK506 in blocking lymphokine gene transcription 
(Watson et al., 1999). Rapa blocks IL-2-dependent proliferation and the stimulation 
caused by cross-linkage ofCD28 (pai et al., 1994). Azathioprine, and Mizoribin 
inhibit DNA biosynthesis and Cyclophosphamide preferentially affects B-cell 
proliferation. However, regardless of the imm~osuppressive efficacy of each of 
these drugs, they all have severe side effects which limit their potential use in organ 
transplantation. The challenge facing any researcher in transplantation is to find an 
immunosuppression regimen that mitigates side effects especially nephrotoxicity, 
neurotoxicity, thrombocytopenia and altered glucose metabolism. 
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2.3 FTY720: a novel immunosuppressant 
[saria sinclairii, an ascomycete, acts as a parasite on the larva of the cicada Meimuna 
opalifera Walker. Myriocin (lSP-l), a drug with inummosuppressive properties, was 
purified from the culture filtrates of this fungus. In mouse models, ISP-l was shown 
to inhibit allogeneic mixed lymphocyte reaction~ (Fujita et al., 1995), interleukin-2-
dependent proliferation (Miyake et al., 1995), and to reduce alloreactive cytotoxic T 
lymphocytes (Fujita et al., 1994). However, the administration of ISP-l at a dose of 
Imglkg induced severe digestive disorders resulting in the death of the experimental 
animals (Fujita et al., 1995). Due to the immunosuppressive potential of this 
compound, Professor T. Fujita (Taito Co. Ltd) in collaboration with Yoshitomi 
Pharmaceuticals Ltd, performed synthetic modifications of ISP-l to produce a less 
toxic yet more active compound, FTY720 (2-amino-2-(2-[4-octylphenyl] ethyl)-1,3-
propanediol hydrochloride). 
The immunosuppressive effect ofFTY720 is associated with a decrease in circulating 
lymphocytes, affecting both T - and B-Iymphocytes. The mechanism of action of 
FTY720 has not been elucidated but the immunosuppressive effect may result from 
homing of lymphocytes to peripheral organs and/or apoptosis. 
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Figure lA: The chemical structure of ISP-l 
HO OH 
Hel 
Figure IB: The chemical structure ofFTY720 . 
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2.4 Immunosuppressive effect of FfY720: in vivo 
Suzuki et al. (1996) reported that a single dose of IOmg/kg FTY720 administered to 
ACI rats resulted in a rapid decrease in peripheral lymphocytes which returned to pre-
drug values within two weeks. Adachi et al. (1995) described the efficacy ofFTY720 
in prolonging rat skin allografts in a major histocompatibility complex (MHC)-
compatible rat strain. They reported that a dose of>O.03mg/kg FTY720 by 
intraperitoneal administration was effective in increasing graft survival. The 
prolonged survival of the rat skin allograft in a major histocompatibility complex 
(MHC)-compatible rat strain was supported by Chiba et aI. (1996) who evaluated the 
oral immunosuppressive efficacy ofFTY720 in a MHC-compatible and MHC-
incompatible rat skin allograft model. They found that FTY720 significantly 
prolonged graft survival in a dose-dependent manner in both models. Administration 
of the same dose ofFTY720, given either orally or intraperitoneal, resulted in graft 
survival which indicates a good bio-availability of the drug. FTY720 selectively 
decreased peripheral mature T -cells but did not affect bone marrow cells, thymocytes 
or polymorphonuclear cells. Unlike CsA and FK506 the drug had no effect on IL-2 
production even at concentrations of IOOOnM. In addition, the authors reported that 
FTY720 did not inhibit colony-forming bone marrow cells in response to 
erythropoietin, IL-3 or IL6. They concluded that FTY720 is an orally active 
compound which prevents acute rejection and that the immunosuppressive 
mechanisms of FTY720 seems to be related to the selective decrease in the circulating 
T-cells. 
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Suzuki et al. (1996) tested the effect ofFTY720 in a rat liver allotransplant model by 
implanting livers from ACI rats into LEW rats. The recipients were divided into four 
groups. Group one did not receive any immunosuppressive therapy; group two were 
given 0.5mglkg FTY720 for 14 days; group three received 5mglkg FTY720 one day 
before and on the day of transplanting as a pre-transplant dose; and group four were 
administered 5mglkg FTY720 three and four days after the transplant. The results 
showed that the rats which did not receive FTY720 had a median survival time (MST) 
of 11.5 days compared to 27.5 days of those rats who received the drug at a low dose 
for two weeks. The latter compared favourably with the pre-transplant regimen while 
the post-operative administration of the drug had a MST of23 days. No side effects 
were experienced by any of the experimental animals. 
As FTY720 had proven its efficacy in rat skin and liver allografts, Hoshino et al. 
(1996) tested the drug on graft survival after heterotopic cardiac allotransplantation. 
They transplanted hearts from WKAH rats into ACI rats and found that at a dose of 
O.lmglkg or more, FTY720 significantly prolonged the cardiac allografts. They 
reported that FTY720 at 10mglkg induced graft survival of over 100 days in three out 
of five rats which indicated that a short course treatment of the drug at a high dose 
completely prevented allograft rejection to induce indefinite graft survival. In 
addition to the promising effect of FTY720 on graft survival in rat skin, liver and 
heart, Suzuki et al. (1998) found that a pre-transplant dose ofFTY720 significantly 
prolonged the survival of pancreaticoduodenal allografts in rats. 
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The success ofFTY720 as an immunosuppressant agent has not been limited to 
smaller animals. Suzuki et al. (1996) transplanted kidneys from mongrel dogs into 
the iliac fossa of beagle dogs which received lOmg/kg FTY720. The survival rate 
was three-fold that of the control dogs indicating that FTY720 was effective in a 
canine model although the drug was only effective at a higher dose. Nevertheless, no 
adverse reactions were experienced by any of the dogs. In later experiments, Suzuki 
et al. (1999) documented that dose-dependent prolongation was not obtained in this 
model and the discrepancy in dose-dependency may be due to differences in animal 
species and in the different organs tested. 
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2.S The role ofFfY720 in rejection 
Allograft rejection is initiated by the infiltration and subsequent activation ofT cells 
by Th1-associated cytokines (IL-2, and IFN-y), whilst Th 2 associated cytokines (IL-4 
and ILl 0) are essential for xenograft rejection (Josein et al., 1995). Adhesion 
molecules related to T-cell trafficking are enhanced in allografts and monoclonal 
antibodies to these adhesion molecules inhibit rejection. Yanagawa et al. (1998), 
using a MHC-incompatible rat skin allograft model, reported that after transplantation 
there was an enhanced expression ofTh-1 associated cytokines and CD3 messenger 
RNA (mRNA) whereas Th-2 cytokines were un4etectable. When FTY720 was 
administered there was a decrease ofT lymphocytes, not only in circulation but also 
in the allografts yet no effect was seen on IL-2 and IFN-y mRNA. On administration 
of a low dose of CsA, there was an inhibition ofIL-2 and IFN-y mRNA in the 
allografts, but CsA did not affect CD3 mRNA. Therefore, the combination of 
FTY720, which is effective at inhibiting T cell infiltration into allografts, and CsA, 
which reduced IL-2 and IFN-y expression, proved to be synergistic and significantly 
prolonged allograft survival. 
T-cell infiltration into transplanted allografts is essential for rejection. Yanagawa et 
al. (1999) assessed the influence of FTY72 0 on T-cell subsets ofT-cell infiltration 
into grafts and noted that the effect was not selective to T-cell subsets including 
CD4+, CD8+, CD25+CD4+ and CD25+ CD8+ cells. The authors proposed that in 
allograft rejection, cytotoxic differentiation of infiltrated CD8+ T -cells requires 
intragraft Th-1 associated cytokines which are produced by infiltrated CD4+ T-cells. 
Therefore, because FTY720 inhibited infiltration of CD4+ and CD8+ T -cells into the 
graft, allograft survival was prolonged. This was supported by Kunikata et al., (1999) 
who reported that acquired immune tolerance by FTY720 treatment had been 
described in rodents who received anti-CD4 and anti-CD8 antibodies. 
Kunikata et al. (l999) suggested that the improvement of renal allograft survival 
might require lymphocytopenia before grafting. The authors reported that FTY720 
had a preventative rather than a therapeutic effect on graft rejection as, a pre-
transplant administration of the drug caused a significant prolongation of graft 
survival. Anti-lymphocyte serum and monoclonal antibodies to decrease peripheral 
lymphocytes have been used for reversing ongoing acute rejection in organ 
transplantation. Since a single dose ofFTY720 decreased peripheral lymphocytes 
within hours, the authors suggested that the lymphocytopenia contributed to graft 
survival. 
The effect ofFTY720 as a rescue drug for acute rejection was studied by Yuzawa et 
al. (1998), who administered a subcutaneous injection ofFTY720 to five dogs with 
acute rejection following a mismatched renal transplant Three dogs were rescued and 
biopsies taken revealed that the FTY720 reduced cell infiltration into the parenchyma 
of the rejected grafts. 
Another crucial process in organ rejection is the upregulation of expression of 
adhesion molecule on leucocytes and endothelial cells by cytokines such asTNF-a.. 
Li et al. (1997) tested the effect of FTY720 on the expression pattern of cell adhesion 
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molecules and fOWld that in the absence ofTNF-<x, FTY720 had no effect on the 
expression of adhesion molecules including ICAM-l, VCAM -1 and E-selectin. 
However, in TNF-<x-treated human umbilical vein endothelial cells (HUVECs), 
FTY720 enhanced the upregulation ofICAM-l which plays an essential role in the 
capture of lymphocytes :from the circulation. CsA and FK506 do not affect cell 
adhesion or migration. Therefore, FTY720 must possess a unique 
immWlosuppressive mechanism of action distinct :from CsA and FK506 and thus, 
have a synergistic effect on allogra:f;t survival when combined with these drugs. 
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2.6 FfY720 in combination therapies 
CsA-based combination therapies are widely used in clinical organ transplantation to 
reduce the side effects of individual drugs. In order to compare the 
immunopharmacological profile ofFTY720 with the well-documented profile of CsA, 
both drugs were administered either alone or as combination therapy in a rat skin 
allograft model (Chiba et al., 1996). The results showed that the immunosuppressive 
activity ofFTY720 was 30-fold more potent than CsA but that the combination of the 
two drugs was remarkably more effective than the use of either drug alone. There 
was no difference in the blood levels of the drugs when administered alone or given 
simultaneously suggesting that combination therapy did not affect trough levels of 
each drug in the blood. In combination therapy CsA could be used at a sub-
therapeutic dose which would minimise the adverse effects of the drug. In clinical 
organ transplantation, both Azathioprine and Mizoribine have been effective in 
combination with sub-therapeutic doses of CsA in prolonging graft survival but both 
drugs cause adverse side effects. Unlike CsA, the administration ofFTY720 in 
experimental models has showed no severe side-effects even at high doses. 
CsA was reported as being more effective in a T8:t cardiac allograft model than skin 
model (Ochiai et al., 1987). Hoshino et al. (1996) tested the effect ofFTY720 in 
combination with CsA on graft survival in rats after a heterotopic cardiac 
allotransplantation. They reported that a sub-therapeutic dose of CsA was ineffectual 
as a monotherapy but when administered simultaneously with 3mg/kg FTY720 there 
was an indefinite graft survival of six out of seven recipients. However, they reported 
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that the immunosuppressive effect ofFTY720 was better in hepatic allotransplants 
than in cardiac transplants which could be attributed to size or antigenicity of the two 
organs. 
Although the administration ofFTY720 or CsA alone did not prolong graft survival in 
canine kidney allotransplants (Suzuki et al., 1996), combination therapy considerably 
improved survival from 11 days with CsA alone to 74 days with the combination 
regimen of 5 mg/kg FTY720 and 10 mg/kg CsA. The synergistic effect of these two 
drugs appeared not only to prevent acute rejection but also to reverse ongoing 
rejection of canine renal allografts (Kawaguchi et al., 1996). 
Troncoso et al. (1999) tested the efficacy ofFTY720 in renal transplants in non· 
human primates. Cynomolgus monkeys were transplanted with kidney allografts that 
were incompatible in mixed lymphocyte culture reactions. FTY720 was administered 
at 0.1,0.3 or Img/kglday in combination with CsA using doses that maintained whole 
blood concentrations at sub-therapeutic values between 40·20Onglml. The control 
group, which received CsA alone, rejected their grafts within 8 days. FTY720 at 
doses of 0.1 and 0.3mg/kg significantly prolonged graft survival with a MST of 71 
and 63 days respectively. However, biopsies revealed mild rejection in the 
O.lmg1kglday group. Those monkeys that receiv~ Img/kglday had a MST of 48 days 
but two of the five monkeys died within approximately two weeks which could be due 
to complications caused by over-immunosuppression. These results suggest that a 
combination therapy of approximately 0.3 mg/kg FTY720 and a sub-therapeutic dose 
of CsA may have a beneficial effect in other primate species including human beings. 
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FTY720 is a poor inhibitor ofT-cell proliferation as shown by Wang et al. (1998) 
who examined the effect of FTY720 on human peripheral blood lymphocytes (PBL) 
stimulated by PHA or OKTI monoclonal antibodies. Although FTY720 was not 
effective in vitro to block the proliferative responses of mitogen-stimulated human 
PBL, the drug had synergistic effects when added to CsA or Rapa in vivo. This was 
also observed in a rat cardiac allograft model where Rapa, unlike CsA, did not induce 
nephrotoxicity but the combination of these two drugs did have overlapping 
lipidogenic toxicities. The combination ofFTY720 with low dose CsAlRapa regimen 
prevented allograft rejection indefinitely in 4/6 rats (Wang et al., 1998). 
Strepkowski et al. (1998) used the median effect analysis method to calculate the dose 
reduction index values for the synergistic interaction between FTY720 and CsA and 
FTY720 and Rapa in a rat cardiac allograft model. They fOWld that the dose of 
FTY720 could be reduced by 14-22 fold and that ofCsA by 3-7 fold when 
administered as combined therapy. When combined with Rapa, the dose ofFTY720 
could be reduced by 2-4 fold and Rapa by 1-3 fold Therefore, FTY720 combined 
with a low dose of either CsA and/or Rapa may improve the efficacy of a CsA/Rapa 
based immWlosuppressive regimens as well as negate the adverse effects caused by 
CsA alone or in combination with Rapa. 
Thompson (1989) reported that FK506 had a more potent immWlosuppressive effect 
than CsA in liver, kidney and cardiac animal experimental allograft models. FK506 
has shown a lower incidence of acute rejection than CsA in patients Wldergoing liver 
and kidney transplants (pirsch et al., 1997). Hoshino et al. (1999) showed that 
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combination therapy ofFTY720 and a sub-therapeutic dose ofFK506 significantly 
prolonged skin and heart allografts in rats. In order to determine whether 
immunological tolerance would be induced the authors transplanted skin from either 
WKAH or LEW rats into ACI recipients with long-term surviving WKAH hearts. 
The WKAH skin allografts survived indefinitely' whereas the LEW skin allografts 
were rejected within ten days suggesting that donor-specific tolerance was 
established. 
Yamashita et al. (1999) reported that FTY720 significantly prolonged heart and liver 
transplants in incompatible combination rat strains in a dose dependent manner and 
that the drug had a wide therapeutic window (0.05-1 Omg/kg). When used in 
combination therapy with both CsA and FK506, survival was enhanced. Xu et al. 
(1997) tested the combination of pre-transplant FrY720 and post-transplant FK506 
and reported that this regimen clearly enhanced rat cardiac allograft survival. More 
promising however, was that no adverse effects ofFTY720 were experienced by 
either the rat or canine models, and by combining FTY720 with sub-therapeutic doses 
of other immunosuppressive drugs the adverse effects seen with those drugs could be 
reduced or prevented altogether. 
Miyata et al. (1998) tested the effect of FTY720 on xenotransplants and found that in 
the hamster-to-rat model FTY720 combined with FK506 significantly prolonged skin 
and liver allografts but was not effective on heart allografts. They reported that skin 
and liver are resistant to humoral rejection (B-ceU) and are less dependent on anti-
proliferative drugs and that combination therapy ofFTY720 and FK506 probably 
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inhibits xenoreactive T -cell-mediated rejection, but does not sufficiently inhibit B cell 
proliferation. 
In order to minimise the adverse side effects of the immunosuppressive drugs 
presently available, the concentration of the drugs needs to be reduced without 
sacrificing the efficacy of immunosuppressive prophylaxis. CsA and Rapa display a 
synergistic interaction not only in rats and mice, but also in man (Strepkowski et ai., 
1996, Tu et ai., 1995, Watson et ai., 1999). However, although Rapa is not 
nephrotxic the combination therapy of CsAlRapa has lipidogenic toxicities. Thus 
FTY720 may offer an alternative, as it appears to be synergistic in dual as well as 
triple-drug combinations. Immunosuppressive drugs with different mechanisms of 
action but without overlapping toxic side-effects offer the best possible protocols for 
combined synergistic anti-rejection therapy. 
The mechanism with which FTY720 exerts its immunosuppressive property has not 
been elucidated although the effect of the drug on decreasing peripheral lymphocytes 
is unquestionable. Two theories exist; homing of peripheral lymphocytes to other 
lymphoid tissues and! or apoptosis, both of which are discussed below. 
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2.7 Mode of Action: Lymphocyte Homing 
Immunologically mature lymphocytes continuously circulate between peripheral 
blood (PB) and lymphoid tissues. This consists of lymphocytes trafficking from PB 
to peripheral lymph nodes (pLN), mesenteric lymph nodes (MLN) and Peyer's 
Patches (PP) and returning to the PB via lymphatic vessels and thoracic duct lymph 
(TDL) (Butcher and Picker, 1996). As previously mentioned, oral administration of 
FTY720 at 1 mglkg decreased the number oflyffiphocytes in PB and TDL by 
approximately 80% of the original number within 24 hours. No effect of the drug was 
seen in the thymus or bone marrow. Similar lymphopenia has been induced by 
treatment with steroids and Cyclophosphamide however, the decrease in lymphocytes 
was seen in the thymus and bone marrow as well as in the PB. In addition, other 
white blood cells are affected by steroids. The decrease seen in the number ofPB 
lymphocytes after FTY720 treatment is not due to the inhibition of intrathymic 
differentiation ofT-cells or the suppression of the bone marrow. Rather, FTY720 is 
selective for mature lymphocytes capable of trafficking between the bloodstream and 
lymphoid tissues. Butcher and Picker (1996) reported that the integration and control 
of systemic T and B-cell immune responses depended on regulated lymphocyte 
homing. It is possible that the effect ofFTY720 could be seen inducing both cell-
mediated and humoral immune responses. 
Chiba et al. (1997) reported that the administration of doses of 0.1 and Imglkg 
FTY720 to rats caused a decrease in total lymphocytes in the blood and TDL to less 
than 10% of the control and the splencic lymphocytes by 40-80% within 3-24 hours. 
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By contrast, the number of lymphocytes increased in a dose dependent manner in the 
PLN, MLN and PP. The authors argued that because 4J.1M FTY720 was needed to 
induce apoptosis in vitro, and the trough level measured in dogs administered 5mglkg 
FTY720 was less than 20Ong/ml, it was impossible for FTY720 to induce apoptotic 
death at doses ofO.l-lmglkg. In order to establish whether the lymphocytes were 
trafficking between the blood and lymphoid tissues calcein-Iabelled lymphocytes were 
infused into F344 rats. The authors documented that the labelled cells were found in 
PLN, MLN and PP within 3 hours of administration ofFTY720 and no cell death was 
evident. They concluded that after FTY720 treatment, lymphocytes homed from the 
PB and TDL to lymphoid tissues. 
The homing of circulated lymphocytes to lymphoid tissues is reported to be mediated 
by the attachment of lymphocytes to high endothelial venules in these tissues (Butcher 
and Picker, 1996). This occurs via the lymphocyte homing receptors L-selectin 
(CD62L), CD49d/~7 integrin and CD 11 a/CD 18. The involvement of these homing 
receptors was tested by Chiba et al. (1997) who pre-treated calcein-Iabelled 
lymphocytes with monoclonal antibodies to these receptors. After the administration 
ofFTY720, the lymphocytes were completely blocked from homing to the lymphoid 
tissues which suggested that FTY720-induced lymphopenia in the PB, TDL and 
spleen was due to sequestration of lymphocytes in PLN, MLN and PP and not by 
cytotoxicity. 
To elucidate the relationship between the acceleration of lymphocyte homing and the 
expression of lymphocyte homing receptors, Yanagawa et al. (1998) analysed these 
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receptors on T -cells in FTY720 treated rats. FTY720 markedly decreased the number 
of peripheral blood T -cells but had no effect on CD62L, CD49d and CD 11 a 
expression in PB, PLN and MLN. However, there was an increased of CD62L-
positive T -cells and an increased intensity of CD62L expression in the PP of the 
F1Y720-treated rats. This indicated that F1Y720 increases the frequency of CD62L-
positive T-cells by accelerating CD62L-predominant lymphocyte homing in PP. 
Pre-incubation ofFTY720-treated lymphocytes and anti-a.4-integrin (VLA-4) 
monoclonal antibody prevented lymphodepletion suggesting that FTY720 increases 
the expression, affinity or avidity ofVLA-4 expression (Troncoso and Kahan, 1998). 
Altered VLA-4 expression affects the circulation patterns of lymphocytes between the 
blood stream and lymphoid organs and may home lymphocytes towards high 
endothelial venules in lymph nodes and PP. 
To clarify the mechanism of the decrease in the number of lymphocytes by FTY720 
Chiba et al. (1999) analysed the tissue distribution oflymphocytes in peripheral 
blood, spleen and mesenteric lymph nodes after a single oral administration of 
FTY720. PBL decreased to less than 10% of the control within 24 hours and splenic 
lymphocytes were reduced to approximately 60%. fu contrast, the number of 
lymphocytes in the MLN increased in a dose-dependent manner and returned to that 
of the control within 7 days. They proposed that the decrease in peripheral 
lymphocytes caused by FTY720 was due to the modulation of redistribution of 
circulating lymphocytes to secondary lymphoid tissues. To determine the effect of 
FTY720 on this proposed trafficking, lymphocytes from male rats were transfused 
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into strain-matched female rats which had received a single dose ofFTY720. After 
thirty minutes the female rats were sacrificed and the tissue distribution of male 
lymphocytes was determined by polymerised chain reaction (peR) method. The 
FTY720-treated female rats had increased male DNA in the PLN, MLN and PP in a 
dose-dependent manner which reflects the redistribution of male lymphocytes into 
these lymphoid tissues. There was decreased male DNA in the spleen but no changes 
occurred in the lungs and liver. They concluded that FTY720 sequesters circulating 
mature lymphocytes into PLN, ML~ and PP by acceleration of lymphocyte homing 
which results in a decrease in the number oflymphocytes in the PB and spleen. 
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2.8 Mode of Action: Apoptosis 
In order to elucidate the mode of action ofFTY720, Suzuki et al. (1996) tested the 
drug in vitro and in vivo. They found that a single dose of 10mg/kg FTY720 
administered to ACI rats resulted in a rapid decrease in peripheral lymphocytes which 
returned to pre-drug values within two weeks. When they incubated spleen cells, 
isolated from the ACI rats, with 10,sM FTY720, at different time intervals, they noted 
that as the incubation time increased, there was an increase in dead cells and in the 
proportion of small cells, which appeared indicative of apoptosis. Electron 
microscopy of these cells demonstrated the characteristics of apoptosis including the 
absence of surface microvilli, chromatin condensation and formation of apoptotic 
bodies. Furthermore, spleen cells incubated for 4 hours with concentration higher 
than 4+ 1 O·~ FTY720 exhibited fragmentation of chromosomal DNA as revealed by 
agarose gel electrophoresis. They concluded that the lymphocytes were removed 
from the system by apoptosis. 
Enosawa et al. (1996) reported that the mechanism of decrease in circulating 
lymphocytes was either due to cell death or migration oflymphocytes to other 
lymphoid organs. They confirmed that the total number ofPB lymphocytes was 
rapidly reduced after a single administration of FTY720 in rats. In addition, there was 
a decrease ofT-cells in the spleen and liver but no effect of the drug was seen in the 
thymus, lymph nodes and bone marrow. They reported that CD4+ T-cells were more 
sensitive to FTY720 than CD8+ T -cells and B-cells in vivo and in vitro and that 
FTY720 induced cell death selectively in mature T-Iymphocytes. 
3S 
Several pathways have been reported for inducing lymphocyte apoptosis including 
Fas-antigens, which are abundantly expressed in the thymus, and on activated or 
transformed T-lymphocytes (Itoh et al., 1991). The apoptosis of immature 
thymocytes plays a major role in the negative selection that occurs during thymic 
development. Fas-antigens are not expressed in lpr mice due to mutation of the las-
gene. In order to establish whether ,FTY720-induced cell death was related to fas-
antigens, Suzuki et al. (1996) incubated FTY720 with thymocytes isolated from lpr 
and wild-type mice. They observed that cell death occurred in a dose-dependent 
manner in cells from both the Ipr mice and the wild-type mice. The addition of anti-
Fas antibodies to the thymocytes induced a dose-dependent cell death in the wild-type 
mice but not in the Ipr mice suggesting that there is no relationship between Fas-
antigen-mediated cell death and FTY720-induced cell death. The authors then tested 
the in vivo effect ofFTY720 on lpr mice who spontaneously develop auto-immune 
disease with massive lymphoadenopathy due to their mutation (Suzuki et aI., 1997). 
They found that treated mice had markedly reduced weights of their spleen and lymph 
nodes compared to the untreated mice. Apoptotic cells were detected in all the 
lymphoid organs by in situ DNA nick-end labelling. This suggested that FTY720 
therapy induces apoptosis in abnormally expanding lymphocytes of Fas-mutant mice. 
Although the las-gene was not involved in FTY720-mediated cell death, other 
apoptosis-related genes may be involved. The bcI-2 gene is a proto-oncogene that is 
known to inhibit apoptosis. Its gene product Bcl-2 protein was implicated in blocking 
a common:final pathway to apoptotic cell death (Reed, 1994). Contrary to Bcl-2, Bax 
a family ofBcl-2-related proteins, promotes programmed cell death, and the ratio of 
Bcl-2 to Bax may determine cell survival or cell death following apoptotic stimuli. 
(Oltvia et al., 1994). To establish the intracellular role ofFTY720 on the expression 
of Bcl-2 and Bax proteins, Sukuki et al. (1996) cultmed human mononuclear cells and 
human bcl-2 gene-transferred Iurkat lymphoma cells and their neo-type, with 
increasing concentrations of the drug (2-10J.LM). The human cells and Iurkat-neo 
cells showed characteristic apoptotic cell death, as determined by ladder formation of 
the DNA agarose gel electrophoresis, in a dose-dependent manner. Unlike their neo-
type, the Iurkat-bcl-2 cells were resistant to FTY720 treatment. In addition, they 
fOWld that one hour after FTY720 treatment, the .human cells showed a decrease in 
Bcl-2 protein and an increase in Bax protein causing a reduced Bcl-2 to Bax ratio 
which resulted in cell death. The cells which were resistant to FTY720, displayed a 
similar ratio ofBcl-2 to Bax as that of the control cells suggesting that the drug 
displays bcl-2-associated apoptotic cell death in human mononuclear cells. Thus the 
authors proposed that FTY720 might be implicated in modulating a final common 
pathway of apoptotic cell death. 
FTY720 has a similar structure to sphingosine which was reported to increase the 
intracellular Ca2+ ion concentration in the human promyelocytic HL-60 cells and 
consequently induced apoptosis(Okajima et al., 1995). Shinomiya et al. (1997) 
studied cell death in Ill..-60 cells treated with 4-8)JM FTY720 and fOWld that the drug 
activated the phospholipase C-Ca2+ pathway which induced apoptosis in the HL-60 
cell line. When they added a phospholipase C inhibitor, the increase in Ca2+ ions was 
ablated, as was the DNA fragmentation. They concluded that the DNA fragmentation 
and cell death were related to a sustained increase in the cytosolic Ca2+ concentration 
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and that FfY720 acts via intracellular Ca2+ mobilisation which might be the cause of 
the cell death seen in the HL-60 cells. 
Allograft rejection is associated with cytokine release and infiltrating T -cells into the 
graft. Cytotoxic T lymphocytes (Cn,) and natural killer cells (NK) cells have been 
implicated to cause apoptosis via two independent pathways namely 
perforin/granzyme-cell-mediated cytotoxicity and Fas ligandIFas-based cytotoxicity 
(Nakajima et 01., 1998, Lowin et 01., 1994). These cytotoxic lymphocytes produce 
apoptotic molecules including perforin, granzyme B and FasL which are the effector 
molecules in apoptosis. Nakajima et 01. (1998) studied the effect ofFfY720 on these 
molecules in a rat cardiac allograft model. They focussed on the killer function of 
Cn, and NK cells and their apoptotic molecules: The untreated control group 
showed that, during acute rejection, there was an upregulation of perforin, granzyme 
Band FasL. The rats treated with increasing concentrations ofFTY720, showed an 
inhibition of these cytotoxic molecules in a dose dependent manner, which led to a 
prolonged survival of the graft. They postulated that FTY720 either caused apoptosis 
of activated lymphocytes in the graft causing a reduction of perforin, granzyme B and 
FasL, or that the drug selectively inhibited the transcription of these apoptotic effector 
molecules in lymphocytes which prevented acute rejection. 
Matsuda et 01. (1998) studied the role of caspases in FfY720-mediated apoptosis as 
caspases and their inhibitors have been implicated in programmed cell death (Henkart, 
1996). Mouse lymphoma WR19L cells treated with FTY720 demonstrated an 
upregulation ofcaspase-l and subsequently caspase-3 within two hours. The drug 
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induced both nuclear damage and cell lysis on the WR19L cells. No inhibition of 
lysis was observed when caspase inhibitors were, added to the cultures. However, the 
nuclear damage was completely blocked suggesting that caspases are not required for 
cell lysis in FTY720-mediated apoptosis but nuclear damage is involved in the 
caspase activation. 
Shimizu et al. (1998) reported that an in vivo administration ofFTY720 enhanced 
antigen-induced T-cell death of mature cells but inhibited that of immature 
thymocytes. They suggested that two different apoptotic pathways were responsible 
for T-cell death depending on the niaturity of the cell. Both T and B-cells in the spleen 
expressed DNA fragmentation in vitro after 10 J.1M FTY720 treatment which was 
indicative of apoptosis, whereas FTY720-induced apoptosis in vivo (1 Omglkg) was 
preferentially detected in peripheral lymphocytes. They proposed that the 
immunosuppressive effect ofFTY720 could be ail increased susceptibility ofT-cells 
to antigen-induced apoptosis. They found that FTY720 induced apoptotic cell death 
of thymocytes, splenic cells and peripheral lymphocytes in vitro, but caused apoptosis 
on peripheral lymphocytes and not thymocytes or splenic cell in vivo. The authors 
concluded that FTY720 is not myelotoxic but specifically attacks peripheral 
lymphocytes, is cytotoxic to both T and B-cells in vitro, and the apoptosis-inducing 
effect is higher in T- than B-Iymphocytes. 
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2.9 FrY720 in other roles 
FTY720 induced long-lasting unresponsiveness with a low dose ofO.lmglkg in a 
lethal graft-versus-host -reaction (GvHR) system indicating its effectiveness in 
preventing graft versus host disease (Masubuchi et al., 1996). 
Suzuki et al. (1998) reported that although diabetes mellitus is associated with 
lymphopenia, FTY720-induced lymphopenia did not induce autoimmune diabetes in 
the diabetes-prone bio-breeding rat model. They proposed that FTY720 appeared to 
keep the balance between regulatory cells and autoimmune effector cells. 
Immunosuppression tolerance is the ultimate goal following solid organ 
transplantation. Induction of tolerance by a donor-specific blood transfusion (DST) 
prior to transplantation has been used in experimental transplantation models (Jenkins 
and Woodruff, 1971). Antoniou et al. (1998) reported that FTY720 administered as a 
pre-transplant dose significantly prolonged allograft survival beyond that ofDST. 
However, no further enhancement of graft survival was observed when DST was 
given in the presence ofFTY720. 
Graft coronary artery disease is a major problem in clinical cardiac transplantation 
because approximately 50% of patients who survive five years show significant 
atherosclerosis on routine angiography (Schroeder et aI., 1992). Hwang et al. (1999) 
studied the clinical potential ofFTY720 as an immunosuppressant in a murine cardiac 
model using mice that shared major but not min~r histocompatibility antigens. 
40 
Recipients, who do not receive immunosuppressants but survive allotransplantation, 
develop graft atherosclerosis (Hirozane et al., 1995). The authors found that 
administration ofFTY720 suppressed neointimal proliferation and preservation of the 
luminal area. Furthermore, when combined with esA, the drugs prevented 
atherosclerosis altogether. Together with its ability to suppress acute rejection, 
coronary vasculitis was attenuated by FTY720 treatment. 
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3. AIM 
FTY720 has proven to be active as an immunosuppressant drug in rodent and dog 
transplantation models and has not exhibited any major adverse side effects. Baboons 
are the species of choice in pig to non-human pri,mate xenotransplantation, primarily 
because of their similarity in size. This is especially true for orthotopic cardiac 
transplants and for studies that require large blood volumes. The aim of this project 
was to evaluate the susceptibility of baboons to FTY720, with respect to lymphocyte 
functions and numbers, in an introductory study to xenotransplantation protocols. 
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4. MATERIAL AND METHODS 
4.1. In vivo Experiments 
4.1.1 Drug application 
Chacma baboons (papio Ursinus: body weight range 14-20kg, matched per group of 
three) were obtained from The Medical Research Centre (MRC) Delft Animal Unit, 
Cape Town, South Africa. The baboons were brought to the University of Cape 
Town (UCT) Animal Unit approximately one week prior to the commencement of the 
experiment in order for them to acclimatise to their new environment. They were 
housed in separate cages at the UCT Animal Unit. 
FTY720 (Novartis Pharma, Basel) was dissolved in sterile distilled water and 
administered at dosages of 0.3, 0.1 or 0.03mg/kg. The drug was given in a volume of 
2ml/kg when administered by gastric intubation or 1 mglkg if given as a ball of food. 
Three doses ofFTY720 were administered. The:first two groups of baboons (n=3) 
received 0.3 or O.1mg/kglday respectively for three consecutive days (day 0,1,2) 
using a gastric catheter under ketamine hydrochloride anaesthesia (10mglkg Lm. 
Brevinaze, Intramed LTD, Port Elizabeth, SA). The third group (n=3) received 
0.03mglkg for 10 consecutive days. For this group the FTY720 was administered by 
gastric gavage only on the days of blood sampling (day 0, 1,2, 7 9, 12, 15 and 22); on 
the remaining days the drug was incorporated in golf-size balls of maize flour and 
banana. This provided an alternative to gastric catheterisation which would have 
required anaesthesia for ten consecutive days, impairing the feeding process of the 
baboons. To ensure that the food balls containing the drug were eaten, the baboons 
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were starved overnight and the food balls were provided the following morning. The 
administration of the drug in this manner was validated in an earlier experiment; three 
baboons received a single dose of O.3mglkg in food and the FfY720 blood levels 
were measured and compared to the trough levels of the drug in baboons receiving the 
same dose by gastric intubation. The drug levels ofFfY720 were 2.7 ± O.4nglml in 
the baboons receiving the ball offood compared to 2.6 ± 0.3 nglml after gastric 
gavage. 
In order to determine the baseline variability and to exclude the possibility of side 
effects to either the anaesthetic or the vehicle, the first group of baboons was 
anaesthetised and received the appropriate volume of distilled water instead of 
FTY720 (Table 1). This was repeated twice, the baboons monitored and blood 
samples analysed in the same manner as if they were receiving the drug. 
4.1.2 Blood sampling 
In all experiments blood sampling was done when the baboons arrived at the Animal 
House to establish baseline values. The blood was collected Wlder sterile conditions 
in vacutainers containing either ethylenediaminetetraacetic acid (EDTA) K3 for 
haematological assessment and the determination of drug levels, or lithium heparin 
for cell culture and flow cytometry. In the group of baboons receiving 0.3mglkg 
FfY720, blood was taken before the administrat~on of the drug or vehicle and again 
on day 4,7,9, 12, 14 and 21 (Table 1). For later experiments the number of days on 
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which blood sampling was performed were reduced to prevent the possibility of 
anaemia and to minimise stress cauSed to the baboons (Tables 2 and 3). 
Table 1 
PROTOCOLFORBABOONSRECEnnNG 
O.3mg/kg FTY720 BY GASTRIC GAVAGE 
DAY DOSING FBCIDIFF FACS WB DRUG 
PROLIF LEVELS 
-14 ENTRY +. + + 
-
-7 VEIDCLE + + + 
-
-6 VEIDCLE + + + 
-
-5 VEIDCLE + + + 
-
0 FTY720 + + + + 
O.3mglkg Pre-dose Pre-dose Pre-dose Pre-dose 
1 FTY720 + + + + 
O.3mglkg 
2 FTY720 + + + + 
I O.3mglkg 
I 
4 + + 
- - -
7 + + + + 
-
9 + + + 
-
-
12 + + + 
- -
14 + + + 
- I -
21 + + + 
- -
+: analysis performed 














O.lmglkg FfY720 BY GASTRIC GA V AGE 
DOSING FBCIDIFF FACS WB DRUG 
PROLIF LEVELS 
ENTRY + + + 
-
FTY720 + + + + 
O.lmglkg Pr~dose Pr~dose Pr~dose 
FTY720 +" +. + + 
O.lmglkg 
FTY720 + + + + 
O.lmglkg 
+ + + + 
-
+ + + + 
-
+ + + 
- -
+ + + 
- -




PROTOCOL FOR BABOONS RECEIVING 
O.03mglkg FTY720 IN FOOD OR BY GASTRIC GAVAGE 
DAY DOSING FBCIDIFF FACS WB DRUG 
PROLIF LEVELS 
-9 ENTRY + + + 
-
0 FTY720 + + + + 
O.03mg/kg 
1 FTY720 + + + + 
O.03mg/kg 
2 FTY720 + + + + 
O.03mg/kg 
7 FTY720 + + + + 
O.03mg/kg 
9 FTY720 + + + + 
O.03mg/kg 
12 + + + + 
-
15 + + + + 
-
22 + + + 
- -
Days 3, 4, 5, 6, and 8: O.03mg/kg FTY720 was incorporated in food 
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4.1.3 Pharmacodynamic study . 
A pharmacodynamic study was perfonned on three baboons to assess the efficacy of 
O.3mg/kg ofFTY720 at 0, 1,2,4,8,24 and 48 hours. Anaesthesia was induced with 
ketamine hydrochloride (7~ 14mg/kg Lm.) and maintained for eight hours using 0.5% 
hallothane in 30% 02 and 70% N20 administered intra~trachea11y to secure the 
airways during the intravenous infusion of 0.09% saline. FTY720 was substituted 
with distilled water in a later experiment to exclude possible side effects from either 
the anaesthetic or repeated blood sampling. At e.ach time point 10mI of blood was 
taken and analysed for the same parameters as in the experiments with the different 
doses ofFTY720. 
4.1.4 Neutralisation Studies: FrY+aGal-Antibody response 
a-Galactosyl (a-Gal) antibodies are found in high titres in humans and Old World 
primates and playa significant role in hyperacute rejection (Cooper et ai., 1993). 
Since FTY720 is believed to cause a dramatic decrease in both T and B lymphocytes 
and the aGal response is considered to be "T-cell independent", it was decided to test 
the potential ofFTY720 on a "T-cell independent" B-cell response which is relevant 
for xenotransplantation. Three baboons were treated for five weeks with either O.lmg 
or O.3mg/kg/day FTY720 in maize food balls as previously described, or by gastric 
intubation when anaesthesia was perfonned (day -1,2,4,5, 7, 8, 11, 14,21,28,35,42 
and 52). The drug was made up weekly, dissolved in distilled water as a stock 
solution, and then aliquoted for each application and stored at 4°C until use. Alpha-
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galactosyl polymers (Novartis Pharma, Basel) were dissolved in normal saline, 
aliquoted and frozen at -20°C. o.Gal was administered under anaesthesia (ketamine, 
10mglkg Lm) via the saphenous vein at 1 mglkg. The concentration of o.Gal at 
1 mglml was given at a rate of approximately 2ml per minute using a syringe driver 
(Vial Medical SE 200). The antibodies were administered with the drug on days 1, 4 
and 7 after the commencement ofFTY720 (Table 4). 
4.1.5 FfY720 in mice 
C57B1I6+ 129SV mice deficient in lymphotoxin-alpha (L T -0.-1-)were obtained from 
Theresa Banks of the University of Tennessee, Kiloxville 37996, USA. 
C57B1I6+ 129SV mice were supplied by the UCT Animal House. 
C57B1I6+129SV mice deficient in L-selectin (L-selectin-I-) were obtained from 
Thomas Tedder of Duke University Medical Centre, North Carolina, 27710, USA. 
Imglkg FTY720 was administered intra peritoneally to four LT-o.-I- mice, four 
C57B1I6+ 129SV mice and 2 L-selectin-I- mice. One mouse from the first two groups 
received the same volume of distilled water as controls. Blood was obtained from the 
orbital sinus prior to the commencement of the drug and 24 hours after the 
administration of FTY720. The white blood cell count and lymphocyte counts were 
determined using a Technikon HI blood counter. 
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Table 4 
PROTOCOL FOR BABOONS RECEnnNG 
FTY720 and Imglkg a.-GAL POLYMER 
DAY DOSING FBCIDIFFI IgM,IgG,C WB DRUG 
FACS PROLIF LEVELS 
-14 ENTRY + + + -
-5 FfY720 + + + + 
-3 FrY720 + + + + 
1 FfY720 + + + + + 
a-GAL 
2 FrY720 + + + + 
4 FfY720 + + + + + 
a-GAL 
5 FfY720 + + + + 
7 FfY720+ + + + + 
a-GAL 
8 FfY720 + + + + 
11 FrY720 + + + + 
14 FfY720 + + + + 
21 FfY720 + + + + 
28 
-
+ + + + 
35 - + + + + 
42 
-
+ + + + 
52 
-
+ + + + 
O.lmg1kg FI'Y720 was administered from day -5 to day 10 and 0.3mg1kg FTY720 
was given from day 11 to day 27. 
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4.2 Ex Vivo Experiments, 
4.2.1 Haematoloa 
5ml of blood was collected into tubes containing EDTA K3• The peripheral blood 
parameters and differential were determined using a Technicon HI blood counter 
(Bayer, Munich, Germany). 
4.2.2 ImmunophenotypiD& 
Whole blood was tested for cell surface expression ofCD3, CD20, CD4 and CD8 
positive cells by flow cytometry using dual colour analysis. The antibodies used were 
as follows: 
- mouse anti-monkey CD3 antibody coupled to FITC, clone FNl8 (Biosource, 
International, Fleurus, Belgium ) 
- mouse anti-human CD4 antibody coupled to phycoerythrin (p.E.), clone 
SFCII 2T4D I I (T4-RDI; Coulter Coporation, Miami, Florida) 
- mouse anti-human CD8 antibody coupled to FITC, clone B9-11 
(Immunotech, Marseille, France) 
-mouse anti-human CD20 antibody coupled to PE, clone H299 (BI-RDl; 
Coulter Coporation, Miami, Florida) 
The isotypic controls were: 
- mouse IgO 1 coupled either to FITC or PE (MsIgO l-FITC; or MsIgO l-RD 1; 
Coulter Coporation, Miami, Florida). 
Anti CD3 and 8 were undiluted, whilst anti-CD4, CD20 and the isotypic controls were 
made up using 5~1 of the antibody added to 20~1 ofFACs buffer (Appendix A). 
S1 
For the experiment, 40f.1l of whole blood was added to 10f.1l of each antibody (or 
antibody dilution) and incubated on ice in the dark for 30 minutes. The red blood 
cells were then lysed using 2mls of a I: 10 lysis buffer (F ACS 1M Lysing solution, 
Becton Dickinson, Mountain View, California) for 10 minutes. After two washes in 
FACs buffer the cells were suspended in 0.5ml of the buffer for flow cytometry 
analysis using a Becton Dickinson :F ACScan with Cell Quest software. Negative 
controls were set up using isotypic controls of the appropriate antibodies coupled with 
either FITC or PE. 
4.2.3 Whole blood proliferation assay 
Whole blood was diluted I :20 with RPMI-1640 (Bio Whittaker, Walkersville, 
Maryland). 100JlI of the diluted blood was stimulated by 4J1g1ml Concanavalin A 
(Con A; Sigma Chemical Company, st. Louis, USA). The cultures were performed in 
96 well U-bottomed plates (Corning Corporation, Corning, New York) and incubated 
for 5 days at 37°C in a humidified atmosphere containing 5% C~. After 4 days, 
IJiCilwell of 3H Thymidine eH Tdr 6.7Cilmmol,ICN Pharmaceuticals, Inc., Irvine, 
California) was added to each test well and cell proliferation was measured 18 hours 
later by 3H_ Tdr incorporation using a Beckman LS3800 ~ counter. Negative controls 
were performed in the absence of Con A. 
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4.2.4 FI'Y720 whole blood levels' 
Whole blood from each time point was collected in a vacutainer containing EDTA K3 
and kept frozen until the completion of each group study. Blood levels ofFTY720 
were determined by LCIMS on a HP Series II OOHPLC system interfaced with a 
Finnigan Mat TSQ 7000 mass spectrometer. The analytical performance was 
estimated from the calibration curves and from the results obtained with the quality 
control samples, which were analysed simultaneously. The limit of quantification 
(LOQ), defined by the lowest concentration of calibration samples that could be 
quantified with an accuracy of 100% ± 20%, was 0.38ng/ml for the 0.3 and O.1mg/kg 
FTY720 and 0.072ng/ml for the 0.03mg/kg FTY720. All samples were tested in 
parallel to ensure accuracy. The drug monitoring was performed at Novartis in Basel. 
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4.3 In vitro Experiments 
4.3.1 Immunosuppressive druls 
A. Peripheral blood mononuclear cells (FBMCs) 
PBMC were isolated as follows: heparinised whole blood was diluted 1:4 in 
phosphate buffered saline (PBS, see Appendix A). Ten millilitres (mls) of diluted 
blood was layered onto 4mls ofhistopaqueR-I077 (Sigma Chemical Company, St. 
Louis, USA) and centrifuged at I800rpm for 20 minutes. The cells at the interphase 
were harvested, washed twice in PBS, then resuspended in RPMI supplemented with 
10% foetal calf serum (FCS, Delta Bioproducts, Kempton Park, South Africa) and 
200Jlg/ml gentamycin (Biowhittaker, WalkersviUe, Maryland). 1xIOs PBMC/ml from 
two mismatched baboons were incubated together with O-IOJ.LM of an 
immunosuppressive drug in order to evaluate the concentration that inhibits 500Al of 
proliferation (IC50). The drugs tested were Cyclosporine A, (CsA), Tacrolimus 
(FK506), SDZ RAD and FTY720 (all drugs from Novartis Pharma, Basel). The assay 
was performed in 96 well U bottomed plates which were incubated at 37°C in a 
humidified atmosphere containing 5% COz. After 5 days the cultures were pulsed 
with 1 JlCilwell 3H_ T dr and eighteen hours later the cells were harvested and 3H_ Tdr 
incorporation was assessed using a Beckman LS3800 J} counter. 
Controls were set up simultaneously where the drug was substituted with the vehicle 
that they were made up in i.e. either alcohol for CsA, FK506 and SDZ RAD or 
distilled water for FTY720. 
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B. Whole Blood 
Baboon whole blood was diluted I :20 and 100J.11 of diluted blood was incubated with 
50J.1l of Con A (at a final concentration of 4J.1l1ml) and 50J.1l of each drug at varying 
concentrations (0-1 0JiM) as described in the preVious assay. The cultures were 
incubated for 4 days, then pulsed with 3H_ Tdr and treated as for the PBMC. 
4.3.2 Apoptosis 
Apoptosis was measured using the Annexin-V -Fluos staining kit (Boehringer 
Mannheim, Mannheim, Germany). , The exp~ent was set up using both human and 
baboon PBMC, as it had not been determined whether the reagents in the kit were 
cross reactive with baboon cells. I x I 06 PBMC/ml, isolated as previously described, 
were incubated with 0, 3, 6 and 10J.1M FTY720 for 4 hours at 37°C in a humidified 
atmosphere containing 5% C02. After incubation, the cells were washed once in PBS 
to remove the drug, then 100J.1l of the labelling solution (which included propidium 
iodide to assess dead cells) was added and the tubes were left on ice for IS minutes. 
400J.1l of the buffer (Appendix B) was added and cell death was assessed using a 
Becton Dickinson F ACScan. 
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5. RESULTS: Ex vivo: 
S.1 FTY720 at O.3mglkg 
5.1.1 Effect of O.3mglkg FrY720 'on the haemstologieal parameters 
Figure 2A shows the decrease in lymphocyte COWlts in three baboons that received 
0.3mglkg FTY720 (day 0, 1,2), and the recovery phase over 4 weeks. There was no 
systemic effect of the procedure i.e. ketamine anaesthesia, gastric intubation or stress 
induced as shown by the lymphocyte cOWlts during the administration of the vehicle 
(day -7, -6, -5); the lymphocyte COWlt variability was ± 20% with vehicle only. 
Within 24 hours ofFIY720 treatment there was a 59 ± 6% decrease in circulating 
lymphocytes which was further reduced to 70 ± 7% 24 hours after the second dose. In 
all three baboons the lymphocyte COWlts started to recover within 48 hours after the 
last FTY720 administration although the recovery rate was different for each baboon 
as seen in figure 2B. There was no significant effect of the FTY720 on the other 
haematological parameters although there was an intrinsic variation of neutrophil and 
monocyte COWlts namely -58 to +24% for neutrophils and -22 to + 168% for 
monocyte COWlts (Figures 2C and 2D). These coWlts however, remained within the 
normal parameters for each cell type. There was a marked overshooting of the 
neutrophil COWlts 5-8 days after the treatment which was transient and is Wlexplained. 
It may however, be attributed to stress due to the procedure. There was no effect on 
red blood cell parameters or platelet COWltS. 
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Figure 2Bj Effect ofO.3mg1kg FTY720 on the lymphocyte counts in three baboons 
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5.1.2 Effect of O.3mglkg FI'Y720 on T and B lymphocytes 
FTY720 had an effect on both T and B peripheral lymphocytes, the effect being 
slightly more pronounced on T -cells than on B-cells as seen in Figure 3A. Within 24 
hours ofFTY720 administration CD3+ T-cells decreased by 64 ± 8% in the three 
baboons whereas CD20+ B-cells decreased by 39 ± 6%. After two days of treatment 
CD3+ T-cells were reduced by 75 ± 7% and CD20+ B-cells by 51 ± 9%. CD3+ T-
cells recovered quicker than CD20+ B-cells, which only returned to pre-treatment 
values three weeks post FTY720 administration. 
There was no systemic effect of the mock vehicle treatment on T or B cells, however 
the variability was -18%-28% for CD3+ cells and -22%-20% for B cells. 
5.1.3 Effect of O.3mglkg FI'Y720 on T-cell subsets 
Figure 3B demonstrates the effect ofFTY720 on T-cell subsets. CD4+ cells were 
reduced by 73 ± 6% and CD8+ cells by 57 ± 10% within 24 hours and by 84 ± 7% 
and 66 ± 10% respectively after two days of treatment. The recovery ofCD8+ cells 
was substantially quicker than CD4+ T cells. Within four weeks the pre-treatment 
values of CD4+ and CD8+ cells were recovered. 
A small percentage of double positive CD4/CD8, cells (1.3%,3.4%,6.9%) were seen 
in circulation and in the post treatment phase two of the three baboons showed a 
marked increase of these cells (11.1% and 10.5%). 
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5. 1.4 Effrel Q(O.3mglke; FTY720 on u ";''0 whllie blood proliffnltion 
FiguJ'(: 4A 5how5 the re5ponse of whole blood 10 the mitogen Con A befoJ'(: and after 
tJ'(:at mcnl with FTY120. The background, in the absence of stimul"" and the mipon!ie 
to Con A was stable prior to drug ini tiation i.e. day -14. -7. -6. -5 and O. The 
stimulation index for these time poinls IIo'aS between 40-300 in mipon~ to Con A. 
T'hcre was a dramatic de~reasc in Con A st imulation after the drug WI5 administered 
vit. pre drug values of I ]000-27000 were reduced to 100-700 cpm. In I ",hole blood 
assay this dt(:reasc in proliferation almost certain ly COtlld be dUC' to. del:rcased 
I)'mphocyte COtuit however. figure 4B shoW!! when proliferation (Le. response to Con 
A) was cOrTr<:1cd by lymphocyte count s (i.c. cpmllJlIO~ lymphocytes) there was I 
de<:reasc of up to two logs. 
Since then: is no linearity between cell conccntrntioo and pro l ifcrnt ivc response to 
Con A in the "hole blood proliferation assDy. the tulrcsponsivclle» is difficu l! 10 
interpret. However. me prolirerative response in two OUI of me three baboons was al 
the 10weSI on day4 when the Iymphocyt~ e()tu11S were already start ing 10 rccover. so 
one can assUlllC th3l FfYUO does ha\'c an affect on the funrlion o f peri ph ern I blood 
lympboc)1es. 
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5. 1.5 Cond " si"" 
O.3nlglkg FTY720 0" three successi~'e days caused n rapid. dramatic efTe(:t on the 
number of ptriphcrnllYnlphoc}1es within 24 hours and th is efTe(:t was apparent on 
both T alld l1-cells . The prol iferative fWlction of circulnti"g lympllOC}1CS was also 
affected as seen in the whole blood proliferation assay. No obvious sidl" effects of the 
drug e.g. vomiting or respiratory problems Wl"re encowltered by any of the three 
baboons tested although there was a transient loss in body weight in one of the three 
lnlboons (Table 5). This was likely du~ to an imP1'ired feeding after the anaesthelk. 
Although the body weight was back to pre-drug values within twO days after the laSI 
FTY720 trcBlnlertt. it was decided thaI frequent bleedings. which require anaesthesia, 
werc responsible for thi s weight loss and further eXJ)l"riments would be monitored at 
less time poinlS. It was also noted tha1thc time required for the animals 10 fall asleep 
after administration of the ketamine was markedly accelerated on the third d.1Y of 
treatml"nt. 
FTY720 had 00 effect on any other parameters tcsted. 
Tahle 5 Body ..... eighl of baboons 
#205 #206 #21 0 
5.2 Pharmacodynamic study (PD) of O.3mg/kg FTY720 
5.2.1 Kinl'lk effe~t o(O.3mWkg FTVnO on lymphofvte fount ~ 
The lymphocyte counts of aU three babooos were decreased within 1-2 hours of 
~"Y720 treatment. A maximum decrease was seen after 24 hours when there were 77 
± 3% of the pre-drug lymphocyte values. This decrease was still observed 24 hours 
Inter i.e. 48 hours after the first administration ofFTY720 (Figure 5A). 
~ . 2.2 Kinl'lic effect of O.3mglkg FTY720 on T and 8-«11 \ 
Figure 5B shows a rapid and steady reduction i:!. both CD3 + T -1:eHs and CD20+ B-
celLs. Within 24 hours CD3+ cells decreased by 83 ± 5% and CD20+ cclls showed a 
lcss pronounced decrease of 52 ± 4%. These resul ts compared favourably with the 
datil of the O.3mglkg FTY720 over 3 days. 
S.2.3 Kinetic tffect ofO.3mglkg FTY720 on T-ctll subsets 
CD4 + T-eells were only slight!)· more affected lh;m CD8+ cells 115 shown by figure 
5C. CD4~ cells were reduced by 89 ± 1% and CD8+ cells wcre reduced by 82 ± 1%. 
" 
There was an increase ofCD4JCD8 double pos ilh'e cdls in two oul of the three 
baboons vi:r.. I.W. up 10 3.7% lind 6.1% up 10 9.7%. 
!U.4 Kill et'" effeet of O.3mg/k1!, FT\,720 on Vob olt blood p rolifenll ion 
Within " holU'S there was a de<:Tl'ase in response 10 Con A whi<:h was al ilS mll:dmllm 
24-48 houu after the treatmenl (Figure 5D). This followed the d«rease in 
lymphocyte eOlmlS. When the proliferation was e~'ed by Ih¢ lymphoc}1t counts 
(i.e. cpmll+106 Iymphocytes) tile stimulation inde:( dropped from 137 :t 6% a' 0 OOUl'S 
to 10 ± 6 at 48 hOlln (Figure 5E). 
!1.1.!'i Kinet ic dfecl ofO .3 nu;:lkg •• \'720 on edl ,J u lh 
Anna-V staining wu applied to Ihe PBMC collected at each time point during the 
PK study. No apoptosis was observed in the baboon blood al any time point although 
in eontrol ex~rimfT1ts. using the !lime deteclion system. apoptosis "'lIS induced in 
hlll11.1n PBMC after 4 bouT$ in Ihe presenct of 3"moJ ."'TY720 (Figure SF- apoptOl.ic. 
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5.3 FT\,720 at O.IIlIg/kg 
~.3. 1 ErrtN 0(0. 1 IIII/ml rrvno On Iht h"tm~lologiu l p~l'lI nl tltn 
Figur~ 6A shows Ihe eITect oro. 1 mgfkg ofFTY120 01\ !he Iymphocytt counts oflhree 
b<lbooru. during drug IIdminislmlion. nnd ,he fC«»'C')' jlIuuc u~'" h' u "'cd.~. Withi" 
one !by Oflrtatmem there was D sligIJl decrease in circul~tlng lymphocytes by 17 ± 
IN which was funhcr reduced 10 49 ± 7"/. Rf'ler the second dose. The lymphocyte 
tounl$ conlinued 10 drop 10 58::; 7% (Figure 68) 11',,0 ds)'1 Bfter the last Ddminislrntion 
of FTY720 whith suggests an aecumuwtion oflhe drug. Pre-drug \ll lucs "ere 
lUovered three d.'Lys hiler i.e. day 7. 
Thcre was no cffect or tlle FTY720 treatment on any other haematological p.lm~ttB. 
~T;t l Errrct orO. lmg/ml FTY72n on T 3011 II Iympbnn·tc, 
The cmct oro. 1 mgfkg FTY720 on T and B<ells was simibr to thaI seen wilh thc 
higher dose ofO.Jmglkg FTY720. Figure 7A shows the effect of the drug OU COJ t 
and CD20+ cel ls. CDl'" T<dls wert slightl) more reducc-d Ihan CD20+ B<ells "i~ 
T <ells were reduced by 52 ± r~ and I}-ulls wef'C reduced by'; I ± 11 -•. Two days 
lifter Ihc la5\ dose of FTY720 (i.e. dlLY 4) CDJ .... «"Us "ere reduced by 59 :t 11% and 
C020 + cells were reduc~>d by 64 ± S'Yo. 'Ille recovery of B-ulls was once ugain 
,I"""'cr than the T·cells thai were b.1CIr.: 10 the pre·drug levels within one I'ocelr.: . 
" 
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5.3.3 Eff~CI of 0. 1 mglm l FTY720 on T-... ~ II subsflS 
CD4+ T-cells were slight ly more affected than CD8+ cells as seen in figure 7B. After 
m'O da)'l; of treatment CD4+ cells were reduced by 52 ± 13% and CD8-,- cells by 30 ± 
13%. On day 4 the reduction was 55 ± 9% and 44 ± 31% respectively. Both T-edl 
subsets were at least back to pre-drug values on day 7 although C08+ T- cell counts 
showed an overshooting. As secn with the higher do~ ofFfY720 there were a small 
nwnbcr of double positive CD4/CD8 ce lls thlll IllCrcascd after FTY720 treatment i.e. 
4.7 ± 1.5% 10 9.8 ± 2.1% 
5.3.4 Erred of 0.1 me/ml FTY720 on ex ' ·i .... ' whnlf blnod proliferation 
The response to Con A was decreased dramatically in two oflhe threc baboons 24 
hours after the firsl treatment. Baboon 209 showed a less potent but steady reduction 
In response to Con A. Two daYli aner th.., c~sSlllion orlhe drug L..,. u..y 4, all thn;c 
baboons had a decreased response to Con A although baboon 207 had already started 
to recover (Figure SA). When proliferation WIlS corrected by the l)mphocyte count~ 
(I.e. epm! 1 + 106 lymphocytes) "decrease of 1.5 logs was observed ( Figure 8B). By 
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0.1 mg/kg FIY720 on three sucussive days induced a leu dramatic effect than tile 
higher O.3mg/kg dose. TIle decrease in circulating lymphocytes was very modest 
after the lirst dO!ie of FTY720 however. two days . fier the last dose t~re was still a 
58 ± w. decre~. Five day, after the cessation of tile: drug the 1)T\1phoq1e eOlUlts 
recovered which demonstrates a transient panial lymphodepletioo. The effect WlI5 
secn on both T and B-cellJ. The proliferative function of circulatinglympOOc)1es was 
also affected as secn in the whole blood prolifo:J.tion assay. 
No side eff«ls orthe drug were encOlUltered by any of the three baboons tesled 
however. as S«'n with tile previous lrial orO.Jmg/kg "TI720. the body' .... cigll1 
fluc\l.laled during the period whilst tbe dr\lg .... u being IIdministrated crable 6). 
Tallie 6 Body weight of baboons 
" 
5.4. FTY720 at O.03mg/kg 
5.4.1 Efffi'l ofO.03m2/",1 FTV720 on the haemalologiul !lllram~lfrs 
The lymphocyte COUllts were rtduced in two aflhe Ihrec baboons in rtspoo~ to the 
low dose ofO.03mglkg FTY720: the third baboon. 11219. showed csSt'luial ly no 
1)11lphOC)'lC decrease Ihrougboul the ten-day administratiOll of the drug. Figure 9A 
stw"''S the lymphoc)1c depiction in the tWO baboons which was 42 lind 56~. within 
one day and rcached 60-80% by day 7·9. The COWlts had recovered to pre-drug Ic\'c]s 
hy d~y 22 (Figure 91J). 
There was no e/Teet oflhc drug on the other haematological parameters. 
S .... 2 t: rrccI or O.03mglml flynO on T mo d R-t\"mpho('\·It~ 
Two of the three baboons showed II reduction of both T· and B~ells within om day of 
FTY720 adminislrnlion as seen in figure lOA. The CDJ+ T -cells in baboons 23S and 
263 were reduced by 60'10 and 47% respedively after the first dose and Ihis was 
further reduced to 75~ and 8~ rt'SpCClively by day 7. The Iymphocytc cowns had 
TCCO\'ered to prMlrulllevcls by day 22. 
CD20~ R-«lIs wcre les.s affected but neverthelcss werc reduced by 43% and 17% on 
day 1. These figures reached 74% amI5t'i% by day 7. As seen in hig/R:r doses of 
FTY120. the recovery ofT-celis ""'as milch quicker than B-«JJs. On cia) 22 ".,hen the 
experiment was terminated, baboon 235 had still oollTached the prc-drug Icvels of 
CD2O+ B-celt6. 
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FTY O.03mg/kg : Oecrease in T - and 8-cells 
(%) 
'OOr-----------------------, 
tleyrC I"' ;'" Dec .. !.... n T and 8..".\1, ItI t"", ba",-" ...... ed .. ,,11 0 Ol"'l!flt8 rrvno 
5.4.3 UTt('1 o(O,Olmg/ml m '120 on T::«11 ~ubo;l't. 
CD4' T ",,-ells were shghtl\ InQfC' afTccted lhan CDS .... T .cells In tnc two respondlRg 
baboons us SC'I.'n mfit;ure lOB CD:!; cells .... 'efC rooIl:OO~' 65°" and 43°·" In the two 
baboons and these ligum; lncrtased to 88'" and 91~ on day 7 CDS+ T -cells 
dccrell5l'd bv so--. and 49"'0 wnhlR 24 hours and these figures Increased to .52"'0 and 
III lymphoc~1e OO\l"t~, ne\erlncles.~, had a ~trong Imbalance ofCl)4+ and CDS· T-
cells C~- T -«lis decreased up 10 40". II) da) 7 "hereas (.-08· T-cell numbers 
more than doubled on da\ 7-I2(rlijure lOCI 
" 
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FTYO.03mglkg: Decrease in C04+ and CDS+ 
cells (%) in Baboon 219 l 




tocurr IOC; Effect of 0 Olmgikll FfY72G QII CJ)41- and CD8+ T -«lis in b.b\>Qn 219 
.. 
5AA Effect ofO.OJmglml fow rV720 00 oX ,·r,., whole blood pronerll tioo 
Duc to a tcchnical crror no rcsults could be rescued for pre-drug. day 0 a nd day 1_ 
HowCI'cr, by day 9 all thnx: baboons had $hmln a dc-crease til response to Con A as 
compared to day 2 results Al though baboon 219 had shown no decrease til 
lymphocyte COl.lnts after lreatmcnt. then: was a len_fold redUCllun In response tu Con 
A on day 12 compared \11th day 2 ThiS suggC'STS That I)mphocytcs arc mtnnsically 
less rcsponSI~C 11.1 mllOgeos after fTY720 Treatment All three baboons had recovered 
fully by day 15 (Figure 11 ) 




Days of treatml1lt 
" ~ ~~~" ~-~ 
t CoM Q>3 
fllluft II; Effetl of 0 O]nlgikl! FTY720 on Ihe r~ of Con A in whole blood 
" 
5.'1.5 Coodulion 
Two ofl~!bree baboon$ !.reate<! with O.OJmgl\r:g FTY720 showed a response to the 
drug. As x-en with the higher doses orthe drog, CO) t l)'mphocytes were more 
redLlCed than CD20+ cells and C~+ T -cells were more affected than C08+ T .cells in 
t~ respooding baboons. The lymphocyte counts in the other baboon (#219) were not 
affected at aU , Although there I',ere no ~-dflJg mullS (or the whole blood 
prolifel'1uiOl1 _y, there was I significant decr~ in rt$pot1St to Con A as the 
trealmel1l progresstd. This wu also seen in baboon 219 although no drop in his 
lymphoc)1c COWII was observed. This could suggest that t'TV720 does affect the 
function of lymphoc)1C5 el'cn al a low dose. The effect of tile drog ollihe sub-
populations ofT -ceUs in baboon 219 i.e. imbalance in CD4.,. and C08+ lymphocytes 
Is unexplained. 
No side effcets of the dflJg wen: experienced by any of the baboons although the body 
.... -eights nUClllllled.llS seen in the other experimerus using higher doses of FTY720. 
As Ihe dntg was administered in food and the baboons were starved o\'cmight. lhis 
could be Ihe cause ofwcightloS5. 
5.5 Pharmacokinetic Study of FTY720 blood levels 
TIle concentration of FTY720 in tile blood of the OObooll$ aller Irelltmel11 was 
assessed in Basel. S .... ~u;erland. Whole blood was frozen al each time poilU in all the 
experiments. Figll1't" 12A shows tlull 24 hours afte r the first dose of O.3mglkglday 
FTY720 for three dlys., 2.6 ± 0.3 nglnd of tile drug YiIS found in the blood circulation, 
The concentration rose to 4.6 ± O.8ng/mI24 hours after the second dose. This "'IS 
followed by an elimination period " ·ith I ff1(!Dn half·life or2. l da)'s. Allhough the 
concentrnlion of FTY720 cOlTclated with the lymphodepletion on day I and 2. there 
was no correlation between drug levels lind II d«reasc in lymphocyte counts in the 
wash out period. On day 7 the level of FTV720 in the three baboons was 0.6, 1.3. and 
0.8ng/ml ..... hich was ± 20% oflhe FrV720 level on day 2, whereas the lymphocyte 
counts decN'ased by 43, 7J and -4". of the pre-trelllment values, respedively. There 
was II low inler·animal va riability in the drug concentnl1iol1 profiles of the three 
baboons. 
The blood levels ofFYT 720 administered in II single O.3mglkg dose 8ml observed 
o"er a 48·00tir period showed peak conccntrations of2.16 ± 0.58 nglml betwC<!'n 2 
and 24 hours (Figure 128). lltereafter, the blood concentraTion of FrV720 decreased 
with a mean elimination half· life of 36 hours (CV32"/o) betwem 24 and 48 houlS 
(Table 7), 
Administration ofFfY720 at 0.1 mgik8lciay for thre<: days resulted in a mean blood 
concentrnlion o r O.6nglml after 24 hOUl3 and this range was mainllined for 7 days 
(Figure 12D). TIltre "'lIS a relatively high inter-animal vlITiability during the three 
days oftttatment. This cOIJld be related to the fnet Ihat Ihe con'enlralions measuR'd 
"'"Cit "cry low and those concentrations below the limit of quarniliealion i.e. 0.38 
nglml "'~ "'" 10 :z ....... No .. liminal ion half_lif~ "ould d~~fOt\! be ".Iculated. 
Administration ofO.03mglkg FTY720 for ten days resulted in a mean blood 
concemration o f 0.161 ± 0. 139 ng/ml after 24 hours. increasing 10 0.3 17 ± 0.167 
ng/Oll aft"r 2 da)'!! (Figunl llC). This reached D nlAlCimum of 0.718 ± 0.025 ng/ml 
after st,·tn days ofln:atmtnt and these concentrations remained in l WO nut of the 
three baboons. There was a rellth'el), low inter-animal variabili ty especially during 
the 0-7 day period. 
T II 7 ". CONCl<' Nl'RATIONS OF FTV720 (' I I) , , mng m 
n\lr. t-') .... oos., ... IIOOS:r. ."1OOS1' t .~, C\1%) 
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5.6 a -Cal polymer + FTY720 al O. t or O.3mglkg 
In a previous co llaborative study performed in Basel and in our laboratory three 
groups of time baboons per youp were administered Alpha Galactosyl (o:Gal) 
polymers o f differem polymeris3tion degrees and one group received the vehicle i.e. 
salille. The rat ionale is that these polymers contain polylysine thm has been sho ... n to 
neutralise anti-aGa! wlIibodies which are fOWld ill high titres in humans and Old 
World primates. These naturall y occurring antibodies arc knov-n to play R significant 
ro!e in h)-peracute rejection. The results sho"""Cd thai after the infusion of the 
polymers Ihere was a rapid and reproducible decrease of the natural anli o:Gal IgG and 
IgM. The tilrcs oflhe antibodies were recovered by 21 days posl administration of 
tile polymers and the return of these antibodies ""as considered due to a de 110\'0 
syntllesis. The saline control had no effect as el<pecled. Since fTY720 causes a 
dramatic decrease in both T and B lympooc)1es and the (lGa! respo nse is considered 
to be "T-cell independem~. it was decided to lest the potential offTY720 on a ' 'T-cell 
independent"" B-cell response which is relevant for xenotransplantation. 
Figure 13 shows the effect ofFfY720 in the presence ofaGal polymer on the 
lymphocyte counts in three babooflS. All three baboons showed a drastic decrease in 
cowus 85 seen with FTY720 ~lone (data shown in earlier uperiment). Figure 14A 
and 14B shows the effect of FTY720 and (lGal polymer on T and B-cell s and 
CDh /CDR+ T-ce ll s respectively. These results correlate ..... ith the resul ts seen .... ·hen 














FTY 120 ~ IGII Polymer 





~ or " ...... _"1 
FTY720. _0..1 Polyme. 
.. 
i __ "2'V 
--:ru 
T· end Ikln Dec, ... (mun:!. SO, n-ll 
, ~--------------~ 
.,. , • • " " Oo,..f I . ...... ~' 
I "yr, IH' '. !)ft,l't'a ... orT ...... K ~.fh .nor FfnlO . (1(;alI'QI)''''''' 
FTV720 • _Gal PoIrmtr 









• • " 
tIl!'" ! ~ II ; '. D«sltl~ In CD·h ocd COS- I}mphoc\,.. lit.". neal_II 
,,'I h ..,.Y71(l aGal PoI)'m..-
" 
Figures J 5A. J S8 nnd 15C (resul!s courtesy of Nov art is Pharma. 8 asel ) show the 
cITect ofLhe uGal Polymer injections (I rnglkg on days I. 4 and 7) on anti-uGal and 
Lhe haernol}1ic ti tres in the presence of FTynO treatment. The results wcre 
compared to historical controls using the &lime flo-,il Polymer in the absence of 
FTY720 (earlier collaborative $Iudy: data not shown). The baboons responded to the 
injections with II marked dec rease of ami ·o:GallgMs and JgGs. and a corresponding 
drop of haemol)1i<: activity 10 background levels lhroughoulthe treatment period. 
Thc~ 1'.'115 however. II rebound on day 7 which decreased after the last injection. 
Figure] 5A sho\\'S thlll anti-aGal lgM recovered 10 levels slightly lower thnn the 
starting \'III~ on day 14-28 and remained 3tthi5 level up 10 day 52. In contrast. the 
anli-aGal IgG lilfes observed on day 14-28 were higher than the initial value! and 
continued to increase from day 35-n (Figure 158 ). The haemol)1ic liltt'S were batk 
10 pre·trcolment va]\1C5 on da)'S 2] ·28 (Figure ]5C). These: resul!.!l indicate thai 
~1'Y720 trcaUnCf1t did not pre\'cntlhc rCCO\'ery ofanu-uGal lgM. JgG IUld haemOI)1ic 
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5.7 ITY720 in mice 
The rcal mechanism of a~tion ofFrY720 has not ~n ~stabl i5hed although it is 
bcli~'ed 10 be ~ilher due 10 apoplOs;s oracth'lued Iymphoc)"t~s or homing to 
peri~l"Rl 1)1T1phoid lissllt. In the lalt~r . the circulating l)"mphoc)1~J arc btli~ved to 
horne to lymph nodes and r eyer' s Patches through the intenll:tioo of lymph tlOrl1 in& 
n:ceptors includiog CD62L lIud int~l l~ukin-2 (1L-2). Table II shows the decrease in 
white blood ~el1 COWlES (WOCC) 24 haurs aft~r I m&lkg FrY720 _lIdminist~red 10 
four L T -0.-1- mice, 4 wild.t)pe C570 V6+1 29SV mi~e and 2 t,.s~leclin.J- mic~. On~ 
L T -0../. Il"IOU.'e and on~ wild·type' moll5C rec~i\'ed distilled wat~r only ~ cootrols. 
TahI r II : II10ust wh i l~ blood tell tou nts p t"i" and POSI Imgll;:g F"TV710 






LT-a -/- I 45.1 5.52 g7.11% 
LT-o.·/- 2 49.23 10.38 78.9% 
L 1"-0.'/' 3 45.]1 J.25 92.11% 
I T·a·' ·4 49.43 21.31 56.9% 
C57BV6"'129-! 13.04 3.0 73.7% 
CS7BV6- 129-2 7.51 2.' 7].4% 
C57BV6.,. 129-3 9.47 L9~ 79.5% 
C57BII6+129-4 5.52 0.76 86.2% 
i..-seleclin·l· J S.! 8 0.76 85.] % 
l ·seleclin·i· 2 ! 4.35 ] .77 73.7% 
L T- a-(romroJ) 14.07 11.20 11.9% 
C578/16+129- 7.U ,., 5.'" 
(control) 
" 
The \\ )ute blood cell counts were slgnJlicanlly reduced tn all oftoc L Ta·,· mice that 
r~'Cel~ed nY710 with 8 mtan dtxrease orn 1°, •. The wtld-type C57B11611 129SV 
79,5'. The cOI1t(ol L Ta- - ulice that received the vducle only Sholl cd on 11 9". 
dI.."Co.:a5I.: \\ hcll,:as the WUCC of the Wild-I) pc conlrol muw.e was reduced by 5,9" •. 
Thi:sc sllghl t\."ductl\l1\S were almost cerIBinl} du.: 10 stress or a drop In blood ,olumc. 





• Pt., F'!Y no 
cuu L-s.~ LT-aI~..j. C!l7~ ..... ) 
,c.., 
Ellyn 16; Dca....., ill oboob~ I)lIIfIboI;)tt _Sl~ LTn..!- ""0:. (jmU6Jc]~S\ 
IJII~~ IJId L-ldeQ m-J lIII;;c H houtuftet Ilx IIdmimltrabOf1 0( 1 ma'q; 
FlI;\Un: 16 sho\\") 1":11 24 houn Incr I m¥,\:¥ FTY720 \\"115 JldmmlSlered, tn.: Il1e.;ln 
3b50IUle Innphoc)1e count w.os reduced by 84 5°, in LTa- _ mlCt, by 94'. In the 
<,:S7BI,6~ 12QSV mice: aod b), 86 "'. In II\( L·~kcun-, - mICe The coouol L Ta--
" 
mouse showed a 16.7% decrt:asc. The decr~ase in the absolute lymphocyte f;ountS in 
the two control mice could be due to strC'$li or lou of blood. 
" 
5. RESULTS: in vitro: 
5.S Effect of Immunosuppressive drugs on Baboon Mixed 
Lymphoc:yte Culture (MLC) 
Figu!'!:; ! 7A shows the ~sponse of mismlL\ched ooboons in a MLC. to various 
eoneemrDtions ofCsA. 'n le mean lymphocyte reaction (MLR) withom any inhib itory 
agcllu .... 'as 22274 cpm with 11 stimulation index (SI) or6.5. nle reason ror the low SI 
is that most of tile b.1boons had 11 high auto-stimulation (background). the mean being 
379 1 cpm for each PIIir ofbllboo!IS. All tests were perfomled in triplicates and the 
percentage of inhibition wa5 calculated according to the formula : 
......--) x 100 
.,,"bere tho bacltwuund equaJ~ \!III .wm of Ibo cxh I*!oon rllMC .. Rt'MI only.1nd ",a,<",""" 
Sllmulll1lon equili 11M: MLR "n"", babooN ";lhou1 811)' inhibilOf)' <kup. 
Figure 17B and 17C show the response or baboon MLC .... hich "here inhi bited by FK 
506 and RAD rc5p<'Cli\ely. The mean MLK Wll5 I 742xpm with an auto-stinlulation 
of3461 for experimenls using FK S06, and 1626kpm .... i lh II background counl of 
J]]2 for RAD. The SI were ~.6 and 6.S respecth·ely. The high auto-stimulation 
eould once again attribute to tbc low SI. Although each set ofresuits did show some 
lncoosislencics when compared against each othet-. lhe general trend of increasing 
drug (()ncenlI'Dtion causing a COI'Telating decrease in MLC rcspon'iC' (Le. inhibi tion) 
was ~n in all experimc:nts. Tabk 9 shows Ule ICSO of each drug which w~re 
tktennlued by Graph Pad sofu,1U't using the p3ck3ge Graph PBd Prism Version 2. 
OIA. The IC50 IIfC expressed in nMol co(lCcrltrations. 
Baboon MLR + CsA 
,~ , ____ .:elm .. n!. so.c~,-'c·,,-_ __ " 
OODI 00D3 001 003 01 03 1 
CIA uMoI 
fllMn 11,\: InhibtlQ') dfe(! ofClA 01\ BIoboon \u.1t. 
Baboon MlR + FK 506 
Im •• n! So. n-121 
o ~' ________________ --" 
0.00\ 0.000 0.0\ 0.a3 0 1 0 3 
FK 606 uMol 
flun 178: lnhab.m.y ~ffl!Cl off" S06 OIl &boon \llR 
Baboon MLR + RAO 
"0 
(meln! so. n_81 
,~ 
r , , 
'00 
-I 00 T 
• 





" " RAOuMol 
f"tIlv" 171:: ]nlllbltory oIT.." of RAn on IJaboon MlR 
" 
r g bIl' <): IC!WI concenl ralion~ or im mu nOS"IJp res~h (' II ru~' in b~ boon Ml.R 
Drug ICSO 
CsA 100 SnM 
FKSOS 3~ 4uM 
IV'D 212uM 
FTY720 :> IOOOOnM 
fTY720 has ~IJ reported us b.!inl! much nJ(J1\! CtTCCtl~'C in \ I~O lhun In ~ .lro Fi\lure 
I'D sJ!O\.s Ill<! .:1T.:c1 ofFTY720 on buboon MLC In \ 1110 IOj.lM FI'Y720 sno"ed lin 
uthlb!Uon of36,j~," IUld Ihc hlgh.:st dOSl;l of 30j.l..\1 \VIIS not suffiClI:nltu completel, 
mhlb ll the MLR but did cause a 77.7"" mlubulon COl1CcnHlIllons 01"1'TY720 belO\\ 
10~oj showed a mmlmal n .. -sponsc 10 the drtl~ 1lI.! ICj() of~'-YnO was I I 17j.1M 
II dose whlcb IS hkeJ) 10 causc apoplosls and thus could be:. non--SPCClflC effect (c 8 
non-spo:x:ific for mhlbitlon oftht: allo-n:s~) 
o 
Baboon MlR + FrY 720 
(mun ~ so, n'"9) 
0.1 (11 
" w 03 1 1 
FTY 720 uMoi _cc-=~ 
tlg .. u 170: E1Iioc1 ofFn'7W on bobooo MUt 
j 
5.9 Effect ofTmmunosuppressi\,c drugs on Baboon \VB 
Baboon whol~ blood. stimulated with 4/llfml Coo A. WlIS tre:lled with irlCTell!iing 
concentrations of immunosuppressi"e drugs. Figures ISA. Band C show the elTect of 
CsA. FK506 and SDZ RAD re5p«tively on stimulated baboon " 'hole blood. Table 
I 0 demonstrates the mean mD~imwn stimullllion orbabClon WD by Con A. mean 
background counts and meiln SI for each set or expcr;mcnu using the 
immunosuppressive druSS (100% stimulDtion indicHlcs no drug added). The obvious 
dilTcn:n~e in the background counts between the MLC and WB could be attributed to 
the roetal calr serum. "hich is omi11ed in the whole blood Il!iSB)·S. 
FTY720 "lIS no! inhibitory at all even at high doses ofJOflMol and appeared to have 
an wle:cp[ained stimulatory elTect on the whole blood. 
Tnble 10: Erred oflmmUllOSupprt:ssivt drugs on Baboon WD in response to Con A. 
Drug 100-;. RlIckground 51 
Stimulation (cpml 
{(pm) 
CoA 32650 685 99.51 
FK306 19323 60 1 81. 1 
RAD 2%0' 626 91.5 
FTY720 33084 713 76.2 
" 
'" ,~ 
Baboon we + esA 




F;gurf ! SA: En-tet orelA 0<1 Boboon .... hol. blood .1H .... I.l~d WIth Con A 
'00 " --
Baboon we + FK506 
(mlln!:SO,n-1 5) 
,~----c-__ 
0.001 OJlOJ 0,0\ 003 0' 0.3 
FK 506 uMo! 
~i2ure 18B: Effect ofFK <06 00 Baboon who'" blood Slimutllcd wnh Coo A 
Baboon we + RAD 
,~, 
(mun! SO, .... 7) 
I 1 , 75.0 0 
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.1cuu ! Ie: Enect ofRAD on Baboon ,,11010 blood ."mulaled with Con A 
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ne IC50 of C5A aud FK S06 in WB were simil ar 10 those using PBMC (Table II). 
However.tht IC50 ofSDZ RAD in whole blood was six-fold more than in the t>.1LC: 
the MLC is an allostimulation rather than a mitogen-induccd response. nlis result 
may be afT~'(:ted by the "partitioning" oflhe drug from the plasma and red blood t e lls 
when preparing PBMC as doses of approximately I .5-fold C5A but 36·fold more 
Rapam)·cin. a derh'alive ofSDZ RAD. is Reeded for the same response ldata nOl 
shoWTI). 
" 
6 .. DISCUSSION 
Phannacokinetic and pharmacodynamic studies of new immunosuppressants are 
essential to establish dose response and to design new drug regimens for 
transplantation experiments, especially in non-human primates. Depending on the 
drug under study, haematological parameters or immunophenotyping of the different 
lymphocyte populations by flow cytometry can be used as a "read-out' of the drug 
effect. Animal experiments have demonstrated the powerful immunosuppressive 
properties ofFTY720 in rodent and canine transplantation models. The 
immunosuppressive effect ofFTY720, a synthetic analog of the drug Myriocin, is 
related to a rapid and profound decrease of peripheral lymphocytes in the blood 
circulation. Cyclosporine, FK506 and RAD do not affect the number oflymphocytes 
in circulation, but rather their responsiveness to activation stimuli. Therefore, ex vivo 
lymphoproliferative assays may be useful to assess the pharmacodynamics of these 
immunosuppressive drugs. 
Whole blood assays are preferred for pharmacodynamic evaluations since they avoid 
drug re-distribution during lymphocyte separation, and require small quantities of 
blood, thus allowing for repeated sampling for kinetic studies. In this study, 
pharmacodynamics ofFTY720 in baboons were performed using whole blood to 
assess lymphocyte phenotyping and ex vivo lymphocyte proliferation, as an 
introductory study for the use ofFTY720 in baboon allo- or xenotransplantation. 
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Three doses ofFTY720 were tested viz. 0.03, 0.1 and 0.3 mglkg. All baboons treated 
with FTY720 were exposed to the drug. There was a good correlation between the 
dose applied and the FTY720 24-hour trough levels as seen after one or two daily 
doses ofFTY720 administration at 0.03,0.01 and 0.3 mglkg/day. After the third dose 
of 0.3 mglkg FTY720, the mean levels of drug in the bloodstream was ± 0.9 ng/ml on 
day seven, whereas that of 0.1 mglkg FTY720 was ± 0.6 ng/ml in the same time 
period. The ten-day protocol of 0.03 mglkg FTY720 reached a maximum of± 0.7 
ng/ml after seven days, then reached a plateau at this level, in two out of three 
baboons. Thus, there was a clear drug accumulation in the baboons treated with a low 
dose over a longer period. There was a relatively low inter-animal variability in the 
concentration profiles. 
All but one baboon (0.03mglkg) showed a response to FTY720 in terms of a decrease 
of lymphocyte populations from the peripheral blood. The quickest onset of 
lymphodepletion was clearly seen at the highest dose. The pharmacokinetic study 
revealed that a decrease in circulating lymphocytes was already observed between 1-2 
hours after administration of 0.3 mglkg FTY720 reaching 50% after four hours and 
77% after twenty four hours (n=3). This correlated well with the mean lymphocyte 
depletion twenty four hours after the 0.3 mglkg/day dosage, indicating that a sustained 
anaesthesia did not interfere with the effect ofth~ drug. The inter-individual 
variability of the response appeared to increase with a lower dosage of the drug. At a 
higher dose there was little inter-baboon variability in the FTY720-induced 
lymphopenia in regards to T -cells, B-cells, and T-cell subsets including CD4+ and 
CD8+ cells, whereas a strong variation was seen in the recovery phase. The duration 
101 
of the effect was clearly longer after the higher doses of 0.1 and 0.3 mglkglday. 
However, the maximal effect in terms of peripheral blood lymphocyte depletion was 
similar in all three treatments. Therefore, there was no clear dose-response effect 
within the three individual treatments. The data suggests however, that high induction 
doses e.g. 0.3 mglkglday should be used to optimise immediate response and that a 
reduced dose regimen e.g. 0.03 mglkglday should be sufficient for drug maintenance. 
The prevention of graft rejection involves the inhibition of active T -cells and B-cells, 
as delayed xenograft rejection is mediated by cellular and humoral mechanism. 
FTY720 caused a depletion of both T and B-cells in the peripheral blood circulation, 
an effect that is unique to this immunosuppressant agent. Although the effect of the 
drug was more rapid and pronounced on T -cells than B-cells, the effect was more 
persistent on B-cells which took longer to recover to their original values. After two 
days of 0.3 mglkg FTY720, T -cells where reduced by ± 75% and B-cells by ±.51 % 
whereas in the 0.1 mglkglday the e1:Ject on T and B-cells was essentially equivalent. 
The continuous dose of 0.03 mglkg for ten days revealed similar values (on day 
seven) to the 0.3 mglkg dose. The kinetic study compared favourably with the data of 
the 0.3 mglkglday FTY720 treatment. Thus, FTY720 is effective in decreasing both 
T and B-cells in the peripheral blood of baboons. This is not consistent with previous 
reports in other species which suggest that the predominant effect ofFTY720 is on T-
cells (Yanagawa et 01., 1998; Troncosco and Kahan, 1998; Enosawa et 01., 1996; 
Adachi et 01., 1995). 
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There was little correlation between the 24-hour FTY720 trough blood levels and the 
lymphocyte depletion. The correlation was slightly better at very low FTY720 blood 
levels of 0-0.7 nglml, whilst values above a concentration of 1 nglml resulted in the 
lymphocyte depletion being in the maximum range. There appeared to be a threshold 
ofFTY720 blood levels above which cells were affected and consequently left the 
blood circulation. Clear discrepancies between FTY720 blood levels and lymphocyte 
blood counts were also found in the single dose 48-hour pharmacokinetic study, 
where the circulating blood levels ofFTY720 decreased by 30% between 24 and 48 
hours after treatment, whereas the lymphocyte counts remained stable. These results 
suggest that FTY720 accumulates in the tissues and can be detected for a long 
duration before being cleared. Therefore the data obtained in this baboon study raises 
questions about the value ofFTY720 blood levels as a prediction for drug 
effectiveness. 
The effect that FTY720 had on the T-cell subsets i.e. CD4+ and CD8+ cells was 
similar in all three doses ofFTY720. There was a slightly more pronounced effect on 
CD4+ cells than CD8+ cells although CD8+ T -cells recovered quicker than CD4+ T-
cells. These results were in agreement with those ofEnosawa et a1., 1996, who 
reported that CD4+ T-cells were the most sensitive to the effect ofFTY720. Since the 
rejection of allografts has been associated with Th-l associated cytokines, which are 
produced by CD4+ T -cells and are involved in the cytotoxic differentiation of CD8+ 
T-cells, the effect ofFTY720 on dramatically reducing the number ofCD4+ T-cells 
holds promise in contributing to the preventing of allograft rejection. 
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There were some CD4/CD8 double positive T-cells in the peripheral blood of the 
baboons that essentially doubled within seven days after F1Y720 treatment in nine 
out of twelve baboons. This was also reported by Enosawa et ai., (1996) who 
documented an increase in CD4/CD8 double positive T-cells after a single dose of 
FTY720 and proposed that F1Y720 caused apoptosis of lymphocytes and, that the 
CD4/CD8 double positive cells were macrophage cells responsible for scavenging the 
dead cells. Shimizu et ai., (1998) reported that the percentage ofCD4/CD8 double 
positive thymocytes decreased after FTY720 treatment in mice suggesting that 
F1Y720 inhibited negative selection of immature thymocytes. It is possible therefore, 
that the effect FTY720 has on lymphocyte circulation may also affect the trafficking 
of thymocytes to the periphery. 
The increase in CD4+ICD8+ T -cells after F1Y720 treatment in baboons could also 
have been a sign of accelerated T-cell production as a result of a massive 
disappearance ofT-cells due to F1Y720-induced apoptosis. However, no apoptotic 
cells were detected in the peripheral blood of the baboons tested in the 
pharmacodynamic study. FTY720 induced apoptosis at high molecular 
concentrations in vitro and apoptotic cells were detected in the thymus, spleen and 
lymph nodes in mice after F1Y720 treatment (Suzuki et ai., 1996). However, 
Shimizu et ai., (1998) reported that no apoptotic thymocytes or splenocytes were 
found in mice after a single dose of Img/kg F1Y720 although 40% of peripheral 
blood lymphocytes showed signs of apoptosis. In this study, no apoptotic PBMC 
were detected after FTY720 treatment using a read-out that detects in vitro FTY720-
induced apoptosis. However, no attempt was made to analyse the lymphoid organs in 
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tenns of cell populations and immunohistochemistry during the FTY720 treatment, 
since the protocol included follow-up of the post-treatment recovery phase. 
Therefore, it would be presumptuous to assume that FTY720-induced 
lymphodepletion in baboons is not caused by apoptosis. 
FTY720 induced a rapid and marked decrease in ex vivo whole blood proliferation in 
response to the mitogen Con A. Carry-over of FTY720 in this assay does not explain 
these results since the maximal FTY720 concentrations seen in blood after treatment 
were in the range ofO.015).IM (5 ng/ml), whereas FTY720 did not inhibit lymphocyte 
proliferation in baboon mixed lymphocyte cultures at sub-micromolar concentrations. 
The in vitro data shows that the mean IC50 for FTY720 in the baboon MLC was 
> 1 0000 nMol i.e. 10 ).IMol, whereas CsA and FK506 and RAD were inhibitory at 
nanomolar concentrations; the IC50 was 101 nMol for CsA, 34 nMol for FK506 and 
21 nMol for RAD. The in vitro response of mitogen-stimulated baboon whole blood 
to FTY720 showed that the drug was not inhibitory at concentrations up to 30 ).IMol 
whereas the inhibitory effect of CsA and FK506 ·was similar to that seen in the MLC. 
The decrease in whole blood proliferation in the baboons after FTY720 treatment is 
likely to be due to a numerical deficit rather than a functional deficit in the T-
lymphocyte population as the same volume of blood was used regardless of the 
lymphocyte count. However, the nadir for ex vivo proliferation after FTY720 
treatment in the 0.03mg/kg dose was seen on day 4 which was two days after the last 
FTY720 dose when the lymphocyte counts were already recovering. Thus, it is 
difficult to interpret the decreased ex vivo response in tenns of lymphocyte 
unresponsiveness since there was no linearity between the cell concentrations and 
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proliferative response to Con A in the whole blood proliferation assay. However, the 
whole blood ex vivo proliferation in response to Con A was reproducible, used little 
material and appears suitable for efficacy studies of immunosuppressive drugs. 
The infusion of aGal polymers into baboons resulted in a rapid reduction of natural 
anti-aGal IgM and IgG. However, within three weeks the titres of these antibodies 
were recovered. The simultaneous treatment with FTY720 did not prevent the 
recovery of anti-aGaI IgM, IgO and haemolytic titres; within four weeks the anti-
aGal titres had essentially recovered although anti-aGal IgO continued to increase 
slightly up to the termination of the experiment on day 52. 
FTY720 induced a marked lymphocyte reduction in LT-a-/-mice and L-selectin-/-
mice after a single administration at Img/ml. LT-a deficient mice exhibit a 
phenotype dominated by defects in secondary lymphoid organ development whereby 
they lack lymph nodes and Peyer's Patches (Banks et al., 1995). The mice were 
phenotyped in the Department of Immunology at the University of Cape Town and 
found to be true LT-a-/- mice with no lymph nodes or Peyer's Patches. L-selectin, a 
cell adhesion molecule, mediates the attachment oflymphocytes to high endothelial 
venules of peripheral lymph nodes and Peyer's Patches (Arbones et al., 1994). The 
immunosuppressive effect ofFTY720 has been reported to be due to circulating 
lymphocytes homing to lymph nodes and Peyer's Patches and attaching to high 
enothelial venules in these tissues via lymph homing receptors. Thus, the profound 
lymphopenia induced in these mice by FTY720 supports a cytotoxic rather than a 
lymphocyte "homing" effect ofFTY720. However, no apoptotic studies were 
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conducted on the mice rendering the mode of action of FTY720 inconclusive in this 
s.tudy. The wild-type control C57B1I6+SV29 mice were similarly affected whilst the 
lymphocyte counts in the vehicle control mice were essentially unaffected. 
No effect ofFTY720 was seen on the other haematological parameters including 
neutrophil, monocyte, platelet and red cell parameters. The chemistry (data not 
shown) showed normal kidney and liver functioning. No adverse side effects were 
experienced by the baboons although some of the animals had a slight reduction in 
weight. The drug was well tolerated even when administered over a long period as 
seen in the 5-week a-Gal trial where the baboons received O.lmg/kg/day for three 
weeks and the dose was increased to O.3mg/kglday for the final two weeks. 
In conclusion, this study shows that baboons are susceptible to FTY720, and both 
peripheral T -cells and B-cells are profoundly affected by FTY720 treatment. The 
higher dose ofO.3mg/kg is the most effective in terms of a rapid and marked decrease 
in peripheral lymphocytes. The effect is more pronounced and persistent on CD4+ 
than CD8+ T -cells and this translates into reduced ex vivo T-cell proliferation. The 
mechanism of action ofFTY720-induced lymphopenia, which was originally 
reported as preferentially exerted on T -cells, is still controversial. No apoptotic cells 
were found in baboon PBMC isolated after treatment with FTY720 in the 
pharmacodynamic study, although control studies using human PBMC showed that 
apoptosis was induced after four hours in the presence of 3 ~ol FTY720. Although 
FTY720-induced lymphodepletion was observed in LT-a-/- and L-selectin-/- mice 
suggesting that lymphocyte homing to other lymphoid organs might not be a mode of 
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action for the drug, no apoptotic assays were performed to confirm that FTY720 is 
cytotoxic to lymphocytes. Thus the actual immunosuppressive activity of FTY720 is 
still under debate. 
As a follow-up study, it would be interesting to assess, especially in the context of 
delayed chronic rejection and xenotransplantation, whether the FTY720-induced 
reduction of peripheral B-cells also translates in some B-cell immunosuppression in 
"T-cell independent" B-cell models. 
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8.0 APPENDIX A 
Phosphate Buffered Saline (pBS. lOx) 




Dissolve all the chemicals in 1 litre 'of double distilled water and pH to 7.3. 
FACsBuffer 
To 1L of PBS add: 




Hepes ButTer for Annexin-V-Fluos 
10mM Hepes pH 7.4 
140mMNaCI 
5mMCaCh 
Mix all the chemicals together. The buffer is stable for three months at 4°C. 
Propidium Iodide (PI) solution 
Make up 50).1g1ml of PI in the Hepes buffer 
Staining solution for Annexin-V-Fluos 
1000).11 Hepes buffer 
20~ of Annexin-V -Fluos labelling solution from the kit 
20).11 PI solution 
Prepare the above and use immediately 
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